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ABSTRACT 
Sutherlandia frutescens is a traditional plant medicine widely used in South Africa. 
Traditionally, the leaves of S. frutescens are mainly used as a tea, but these traditional dosage 
forms have several disadvantages, including that they are not particularly convenient to 
prepare and store, encourage dosage inaccuracy and are highly susceptible to microbial 
contamination. To solve these problems, dried aqueous extract forms, e.g. freeze dried 
aqueous extract (FDAE) of S. frutescens were prepared, but they, in turn, may still suffer 
from instability and contain mainly hydrophilic phytoconstituents that are poorly absorbed 
and delivered for in vivo activity. Modified forms of the FDAE, i.e. the active 
phytopharmaceutical ingredient (API), may be a better solution. Therefore this study sought 
to prepare liposomes and phytosomes of the freeze dried aqueous extract of Sutherlandia 
frutescens, as a means of increasing the total the surface area of the API, thus improving its 
release and dissolution in gastrointestinal fluids.  
Liposomes and phytosomes of the FDAE of Sutherlandia frutescens obtained were prepared 
using a thin film hydration method at ratios of lecithin: S. frutescens (3:1)  and 
phosphatidylcholine: S. frutescens (2:1) respectively.   The physical characteristics (i.e. 
particle size, size distribution, zeta potential, and morphology), of flavonoid glycosides (i.e. 
sutherlandins A to D; API) as well as content and release profiles of each dosage form (i.e. 
FDAE liposome or phytosomes) at pH 1.2 and pH 6.8 was determined. A validated HPLC 
assay was used to determine and compare the flavonoid glycoside content and release profiles 
of the liposomes and phytosomes. 
 
Both liposomes and phytosomes were successfully prepared, in moderate yields (± 30 %, and 
± 50 %, respectively), using the thin film hydration method. The liposomes had a 
significantly smaller size, lower size distribution, higher zeta potential and better stability 
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than the phytosomes (p < 0.05).  The phytosomes, however, had significantly higher 
flavonoid glycoside encapsulation efficiency than the liposomes (±50 % vs ±26 %; p < 0.01). 
In addition, the release at 120 minutes, of flavonoid glycosides from the liposomes (63%, 
58%, 76% and 46% % at pH 1.2, and 78%, 76%, 87% and 89 % at pH 6.8 for sutherlandins 
A, B, C and D, respectively) was significantly higher and faster than that of the phytosomes 
(52%, 41%, 51% and 39 % at pH 1.2, and 31% 31%, 33%and 45% % at pH 6.8, for 
sutherlandins A, B, C and D, respectively). The differences in release were likely due to 
differences in particle size and size distribution of the two modified API forms. 
Overall, liposomes and phytosomes can be considered promising vehicles for delayed 
delivery of herbal crude extracts. Based on its characteristics (i.e. narrower size distribution, 
and better stability), the liposomes were preferred compared to the phytosomes offering a 
better kinetic release profile. The phytosomes had higher encapsulation than the liposomes 
that may be due to complex formation between the API and the lipid.  
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Chapter One 
INTRODUCTION 
 
Traditional medicine (TM) has in the last several years claimed an increasing share 
of the public’s awareness and the agenda of medical researchers (Ghani, 1990). 
Traditional medicine encompasses knowledge and belief based health practices. It 
refers to health practices, approaches, knowledge and beliefs incorporating plant, 
animal and mineral based medicines, spiritual therapies, manual techniques and 
exercises, applied singularly or in combination to treat, diagnose and prevent 
illnesses or maintain well-being (Wirth, et al 2005). According to WHO traditional 
medicine is the sum total of the knowledge, skills, and practices based on the 
theories, beliefs, and experiences indigenous to different cultures, whether 
explicable or not, used in the maintenance of health as well as in the prevention, 
diagnosis, improvement or treatment of physical and mental illness (World Health 
Organization, 1978). Traditional medicine has been used to treat various diseases 
such as headache, backache, influenza, colds, evaluated blood pressure, diabetes, 
peptic ulcer, liver problems and HIV. And usually the dosage forms used in 
traditional medicine are liquids such as teas and decoctions (Sofowora, 1982). 
 
Sutherlandia frutescens is one such traditional medicine that is popular and widely 
used in South Africa. It is a small soft wooded shrub with pinnately compound 
leaves that have a very bitter taste. Sutherlandia belongs to the family Fabaceae, 
and is known locally by several common names, e.g. Sutherlandia, Cancer Bush 
and Balloon Pea, etc. It generally grows naturally throughout the drier parts of 
southern Africa, in the Western Cape and up the west coast as far north as Namibia 
 
 
 
 
2 
 
and into Botswana, as well as  in the western Karoo to Eastern Cape (Mncwangi, 
Viljoen 2007). Within this distribution there is much variation in the different parts 
of the plant that is used and its clinical uses. Indeed, Sutherlandia is used in 
treatment of various diseases, including type II diabetes, cancer, peptic ulcer 
disease, stomach and liver problems and HIV infection (Ojewole, 2004). 
Traditionally, the leaves of Sutherlandia frutescens are mainly used and usually as 
tea dosage forms (Hess, 2010), but these traditional tea dosage forms have several 
disadvantages. Some of these disadvantages include: time and correct method 
needed for preparation, difficulty in controlling the exact dose, short duration of 
effect of the herbal active constituents, and high susceptibility to microbial 
contamination and product degradation. Due to these disadvantages, there is an ever 
increasing need to use more appropriate and standardized pharmaceutically 
acceptable dosage forms of herbal products, such as S. frutescens, than the tea 
dosage form. 
Solid dosage forms of dried herbal extract, e.g. tablets and capsules, can be used as a 
solution to address some of the challenges seen with the traditional tea dosage form 
of e.g. S. frutescens. For instance, solid dosage forms could provide greater accuracy 
in dosing and good pharmaceutical product quality and stability in terms of shelf life. 
In addition, capsules and tablets containing the freeze dried aqueous extracts (FDAE) 
could provide actions similar to that of the tea dosage form. However, the dried 
extract itself may also have further disadvantages of its own. For instance the dried 
extract powder may not have uniform particle size, adequate flow characteristics and 
might be hygroscopic, all of which may lead to difficulties in the manufacture and 
poor quality of the final product. The hygroscopicity may even lead to instability and 
degradation of the active constituents of the herbal product. The use of the FDAE of 
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S. frutescens to produce a solid oral dosage form of this indigenous medicinal plant 
may thus not be an appropriate solution.  Using modified forms, such as phytosomes 
and liposomes, of the S. frutescens FDAE, could however be a more viable solution.  
 
Liposomes are defined as artificial microscopic vesicles consisting of a central 
aqueous compartment surrounded by one or more concentric phospholipid layers 
(Laouini et al. 2012). They are primarily used to deliver water-soluble substances 
to the body, most likely the skin. Liposomes are formed by mixing a water-soluble 
substance with phospholipids leading to a nanoparticle in which no chemical bonds 
are formed between the substance and lipid. They are useful for drug delivery 
systems as they are capable of entrapping both hydrophilic and lipophilic drugs into 
their aqueous compartment and their lipid bilayer, respectively (Banerjee, 2001). 
Depending on the solvent used, herbal extracts may contain hydrophilic and 
lipophilic ingredients and liposomes have been made of such extracts (Saraf, 2010).  
 Phytosomes are phospholipid-based drug delivery systems that show great promise 
for herbal drug delivery. For instance, Raju et al, complexed the polyphenolic 
phytoconstituents in Silybummarianum with phosphatidylcholine to produce  a new 
herbal drug delivery system, the phytosomes, in which the phytoconstituents had 
enhanced capacity to cross lipid-rich bio-membranes and easily enter the systemic 
circulation leading to augmented bio-availability  compared to that of simple herbal 
extracts (Raju, et al 2011).  In phytosomes the targeted phyto-compounds complex 
with the phospholipid and they have the ability to carry hydrophilic, hydrophobic 
and amphiphilic compounds and thus the potential of giving a better entrapment 
efficacy for the array of compounds that could be contained in a herbal extract. 
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Similar to the liposomes, phytosomes thus also have the ability to carry and deliver 
water soluble phyto-constituents, e.g. flavonoids, etc., that are poorly absorbed, and 
increase their absorption and bioavailability.  It is however not clear which of the 
two, liposomes or phytosomes, would be the more effective delivery system for a 
FDAE of Sutherlandia frutescens. 
 
Collectively phytosomes and liposomes have characteristics that could improve the 
product quality of a FDAE of S. frutescens. They have the ability to deliver high 
concentrations of drugs to disease sites because of their unique size and high drug 
loading capacities. They also deliver drug that has small particle size which in turn  
increases the entire surface area of the drug allowing quicker dissolution in the 
gastrointestinal fluids or blood and a decrease in the dose of the drug required in 
the formulation (Paolino et al. 2006).   
Given the above arguments and disadvantages associated with the traditionally used 
Sutherlandia dosage forms and the advantages that modified forms of the FDAE 
may hold, the overall aim of this present study was to compare the suitability of 
liposomes and phytosomes of the freeze dried aqueous extract of Sutherlandia 
frutescens for solid oral dosage form of this medicinal plant. The specific objectives 
were to prepare and physically characterise liposomes and phytosomes of the FDAE 
of S. frutescens and to determine the drug, i.e. flavonoid, release profile of these 
liposomes and phytosomes. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1  Introduction. 
In this chapter an overview is presented, first, on traditional herbal medicine, 
focusing on the advantages and disadvantages of their use. Then, the South African 
traditional medicine, S. frutescens, is discussed with emphasis on its traditional 
uses, pharmacological and toxicological effects, potentially active ingredients and 
the main traditional dosage forms used. Thereafter, the liposome and phytosome 
delivery systems are reviewed with focus on their properties, similarities and 
differences, typical phospholipid constituents and methods of preparation and 
characterisation.   
 
2.2  Traditional Herbal Medicine. 
Traditional Herbal medicine (THM) encompasses knowledge and belief-based 
health practices. It refers to health practices, approaches, knowledge and beliefs 
incorporating plant, animal and mineral based medicines, spiritual therapies, 
manual techniques and exercises, applied singularly or in combination to treat, 
diagnose and prevent illnesses or maintain well-being (Wirth, et al 2005). 
 
The use of traditional medicine and natural health products is widespread among 
those living with several diseases. Many patients take a broad range of natural 
health products (NHPs) in addition to their conventional therapeutic products. In 
Africa, traditional herbal medicines are often used as primary treatment for diseases 
such as HIV/AIDS and diabetes (Elujoba, A 2005). Medicinal plant products in 
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various forms are available to treat diseases and, most importantly, these plant 
products are the only means of medical treatment for some African communities. 
2.2.1  Advantages and Disadvantages of Traditional Herbal Medicine. 
Traditional medicine has remained the most affordable and easily accessible source 
of treatment in the primary health care system of resource poor communities in 
Africa. There are numerous advantages and disadvantages of herbal medicine thus 
it is proper for anyone considering using herbal medicine to treat health conditions 
to speak with a qualified health professional. Some of the claimed advantages of 
herbal medicines include: 
 Reduced Risk of Side Effects: Most herbal medicines are well tolerated by the 
patient, with fewer unintended consequences than pharmaceutical drugs. Herbs 
typically have fewer side effects than pharmaceutical medicine, and may be safer 
to use over time (Subhedar, Goswami 2011; Gyamfuaaosei, Y. 2013).  
 Effectiveness in Chronic Conditions: Herbal medicines tend to be more effective 
for long-standing health complaints that don't respond well to allopathic medicinal 
(Miles 1998). 
 Lower Cost: Another advantage of herbal medicine is low cost. Herbs typically 
cost much less than prescription medications (Van Agtmael, et al. 1999). 
 Widespread Availability: Yet another advantage of herbal medicines is their 
availability. Herbs are available without a prescription. You can grow some simple 
herbs, such as peppermint and chamomile, at home. In some remote parts of the 
world, herbs may be the only treatment available to the majority of people (Kumar, 
2010). 
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Herbal Medicines however, also have many disadvantages. These include: 
 
 Inappropriateness for Many Conditions: Modern medicine treats sudden and 
serious illnesses and accidents much more effectively than herbal or alternative 
treatments (Bandaranayake, 2006). 
 Lack of Dosage Instructions: Another disadvantage of herbal medicine is the very 
real risks of harming yourself through self-dosing with herbs. There's a very real 
risk of overdose (Knishinsky, 2011). 
 Poison Risk Associated with Wild Herbs: Users run a very real risk of poisoning 
themselves if they don't correctly identify the herb, or if they use the wrong part of 
the plant (Bass, 1990). 
 Medication Interactions: Herbal treatments can interact with medications, which 
may decrease the bioavailability of the drug or could break up the active constituent 
for the drug such as tea interacts with ferrous (Fugh-Berman, 2000). 
 Lack of Regulation: Because herbal products are not tightly regulated, consumers 
also run the risk of buying inferior quality herbs (Fetrow and Avila, 2000). 
 
One of the most popular indigenous South African medicinal plants is Sutherlandia 
frutescens which is widely used as traditional medicine as well as commercial 
products that may be purchased from pharmacies and health shops. 
2.3 Sutherlandia frutescens. 
Sutherlandia frutescens (SF), a member of the Leguminosae family, is a multipurpose 
medicinal plant endemic to South Africa. Commonly known as ‘cancer bush’, it has 
been used in crude form for years by traditional healers to treat a variety of ailments, 
including internal cancers, diabetes, uterine disease, influenza, HIV, depression, and 
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arthritis (Phulukdaree, et al 2010). Various doses of SF leaf powder have been 
administered to humans, and have generally produced no obvious side effects 
(Johnson, et al 2007). However, Mills stated in his paper that known side effects 
include occasional mild diarrhoea, dry mouth, mild diuresis and dizziness (Mills et 
al. 2005).  
2.3.1  Vernacular Names and Nomenclature. 
Sutherlandia is the common English name for the single stemmed plant with the 
botanical name Sutherlandia frutescens (subs. microphylla), a flowering bush type 
plant that grows wild in Southern Africa. It is known by many other names, a 
reflection of the many cultures that have discovered its remarkable properties. Some 
of these common names are listed in table 2.1 (Knowles, C. L. 2005).  
Table 2.1: Vernacular names and nomenclature of S. frutescens 
Name Language 
Cancer bush (English) 
Duck Plant (English) 
Kankerbos (Afrikaans) 
Wildekeer (Afrikaans) 
Rooikeurtjie (Afrikaans) 
Kalkoenbos (Afrikaans) 
Belbos (Afrikaans) 
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Gansies (Afrikaans) 
Unwele (Zulu) 
Insiswa (Zulu) 
Musa-Pelo (Sotho) 
Motlepelo (Sotho) 
Phethola (Sotho) 
 
2.3.2  Botanical Description and Distribution 
Sutherlandia frutescens, is a perennial, short-lived shrub which can grow up to 2.5 
meters high and which produces red to orange flowers (figure 2.1) during the 
flowering season which lasts from Spring to Summer (Collling, 2009). The bitter 
tasting leaves of this plant are compound, pinnate and have a silvery green-gray 
colour. After flowering, black seeds are produced in the green to red swollen, 
bladder-like pods, which grow about 5 cm long and become papery upon drying. 
The plants growing in the coastal regions are shorter and have light gray leaves, 
whereas the plants growing in the inland regions are taller and have darker gray 
leaves.   During a survey of medicinal plants used in the Karoo region, Van Wyk et 
al. (2008) reported that the S. frutescens was the shorter plant (and is considered to 
be female and is used for men’s problems), whilst the taller plant was S. microphylla 
(considered to be male and is used for women's problems).  
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Figure 2.1  Sutherlandia frutescens  
The geographic distribution of Sutherlandia frutescens is variable and widespread 
and the plant occurs throughout southern Africa including the drier parts of the 
Western Cape, Eastern Cape, KwaZulu-Natal, Lesotho, Namibia and the south 
eastern corner of Botswana. (figure 2.2).  According to Xaba and Notten (2003) 
these plants grow particularly in arid areas where the ground has been disturbed. 
 
 
Figure 2.2 Geographical distribution of S. frutescens over Southern Africa 
adapted from (Ifeanyi, 2009). 
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2.3.3 Traditional Uses of Sutherlandia frutescens. 
Sutherlandia frutescens is among the most multi-purpose and useful of the 
medicinal plants in Southern Africa.  Because of its efficacy and safety as a tonic 
for diverse health conditions, it has enjoyed a long history of use by all cultures in 
Southern Africa.  The plant helps the immune system to adapt to unfavorable 
circumstances and is therefore considered an excellent adaptogen (Van Wyk, and 
Albrecht 2008).  
Generally it has been used or advocated for fever, poor appetite, indigestion, 
heartburn, gastritis, esophagitis, peptic ulcer, dysentery, cancer (prevention and 
treatment), diabetes (type 2), colds and flu, cough, asthma, chronic bronchitis, 
kidney and liver conditions, rheumatism, heart failure, urinary tract infections, 
arthritis, viral hepatitis, Chronic Fatigue Syndrome, stress, anxiety and depression  
(Kumar, 2010). Thus, tinctures, infusions and decoctions of the leaves and young 
stems have been used in the Cape from early times, originally by the Khoi and San 
(Nortje 2011) and the other native groups. The latter include the traditional Tswana 
who call the plant  Phetola or “it changes”, meaning that the plant changes the 
course of many illnesses into a favorable outcome and the North Sotho who name 
it Lerumo-lamadi i.e. “the spear for the blood” meaning that Sutherlandia is a 
powerful blood-purifier or all-purpose tonic. 
 
2.3.4 Pharmacological Effects and Toxicology of Sutherlandia frutescens. 
Over the years several preclinical studies have been conducted to investigate some of 
the claimed pharmacological activities (e.g. anti-cancer, anti-inflammatory, 
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antioxidant, and anti-diabetic activities), and the related mechanisms of action, of S. 
frutescens.  
 
Firstly, with regard to the claimed anti-cancer activity it was found that Sutherlandia 
inhibited the proliferation of specific cancer cells by as much as fifty percent (Tai, J. 
et al 2004) and that extracts could kill carcinoma cells. In both cases Sutherlandia 
was only tested in vitro, which is to say in a test tube, and not in animals or humans, 
but these results has led to the conclusion “that these findings warrant further research 
with a view to develop Sutherlandia frutescens extracts for use in anti-cancer therapy" 
(Chinkwo, K. A. 2005). It should however be noted that these studies only looked at 
the effect of Sutherlandia on cancer cells growing in a laboratory, and not its effect 
on cancer growing in a human being. 
Secondly, polar and non-polar extracts of S. frutescens have been demonstrated to 
possess anti-inflammatory and antioxidant effects. The former effect has been shown 
in vitro and in vivo and possibly is mediated via inhibition of cyclooxygenase (COX)-
2 expression (Chen, 2007; Katerere and Eloff, 2005; Kundu et al., 2005; Fernandes et 
al., 2004; Na et al., 2004; Ojewole, 2004), however, researchers at a South African 
university concluded that the strong anti-oxidant activities of the plant might also 
explain its reported effectiveness in treating inflammation (Iwalewa, et al 2007). 
Thirdly, S. frutescens is also claimed to have antidiabetic activity.  Indeed studies 
have shown that it decreases blood sugar levels in diabetic rats, possibly due to its 
pinitol content,  although a preliminary study with pinitol in type 2 diabetic 
individuals did not show encouraging results (Davis et al., 2000).  Nevertheless 
Ojewole (2004) has reported the hypoglycaemic effect of the aqueous extract of the 
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plant in STZ-induced diabetic rats and demonstrated its ability to normalize insulin 
levels and glucose uptake in peripheral tissues and to suppress intestinal glucose 
uptake. 
Finally, Sutherlandia has shown anticonvulsant and antithrombotic activities (Kee et 
al., 2008; Ojewole, 2004) and it is also said to have the ability to serve as an 
adaptogenic agent in stress-related disorders, most likely via attenuation of adrenal 
P450 enzymes leading to a reduction in glucocorticoid levels (and, by extension, 
stress symptoms) (Prevoo et al., 2008; Smith and Myburgh, 2004). Collectively, all 
these preclinical studies have thus presented a reasonable picture of the 
pharmacological activities of Sutherlandia which offers support for its use in the 
treatment of several ailments. 
 
In accordance with the WHO guidelines on evaluation of herbal medicines and 
based on its long history of traditional use in South Africa (Addy, 2004) 
Sutherlandia is also generally regarded as having few toxic effects and being safe 
to use.  Moreover, a toxicity study, sponsored by the Medical Research Council of 
South Africa and the National Research Foundation, has substantiated the safety 
claims. In this study, monkeys were given 9 times the recommended daily dose (9x 
9mg/kg body weight = 81mg/kg body weight) of Sutherlandia dry powder over a 3 
month period and no changes, compared to the control group, were found in liver, 
kidneys, muscles, lung, intestine, bone and biochemical parameters (Seier et al. 
2002).  
Apart from the identification of the above-mentioned pharmacological activities of S. 
frutescens, some of its chemical constituents have also been investigated as possible 
contributors to the effects.  
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2.4 Active Ingredients of Sutherlandia frutescens. 
Several active ingredients have so far been found in Sutherlandia. For instance, L-
canavanine, L-arginine, pinitol, gama-aminobutyric acid (GABA), asparagine and 
secondary plant metabolites such as saponins (triterpene glycosides) and flavonoids 
have been isolated from the plant. Of these, flavonoids may be primary candidates 
for much of the biological and pharmacological effects of this plant. 
Sutherlandia frutescens contains several flavonoids which may be responsible for 
at least some of its biological and pharmacological effects. Some of the flavonoids 
identified include the flavonol aglycones, quercetin and kaempferol, and their 
corresponding glycosides, referred to as sutherlandins A, B, C and D (Fu et al. 
2010). Other glycosides of these aglycones which may be present in S. frutescens 
include rutin, kaempferol-3-O-rutinoside and quercitrin. Sutherlandins A and B, 
rutin and quercitrin are glycosides of the aglycone, quercetin; while sutherlandins 
C and D, and kaempferol-3-O-rutinoside are glycosides of the aglycone, 
kaempferol. The structures of these compounds are shown in figure 2.3. 
 
The flavonoids found in S. frutescens may be responsible for many of the effects of 
the plant.  For instance flavonoids can exert anti-oxidant effects by neutralizing or 
chelating different types of oxidizing radicals which include the superoxide and 
hydroxyl radicals (Tobwala et al. 2014) Flavonoids have also been shown to 
demonstrate anti-inflammatory and anti-tumorial properties (Lai et al., 2007), and 
these pharmacological properties have also been reported for S. frutescens (Kee et 
al., 2008; Ojewole, 2004). S. frutescens shows the ability to serve as an adaptogenic 
agent in stress-related disorders and this may be due to its flavonoids attenuating 
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adrenal P450 enzymes leading to a reduction in glucocorticoid levels (and by 
extension stress symptoms).  The presence and levels of flavonoids in any dosage 
form of S. frutescens may thus have a significant influence on the activity or 
potency of that preparation, whether it is a traditional or modern sophisticated 
pharmaceutical dosage form of S. frutescens.  
 
 Figure 2.3 Structures of the flavonoid glycosides and aglycones. 
2.5 Traditional dosage forms of S. frutescens. 
Traditionally Sutherlandia was used in many ways by the indigenous people of the 
Cape region, the Khoi, Sotho and Nama. It is used topically for healing cuts and 
wounds and as a tonic, it serves as an appetite and digestion stimulant (Thring, et 
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al 2006). Generally, a tea made from the leaves is traditionally used for treatment 
of diseases such as chickenpox, for colds, rheumatism, liver disease and diabetes, 
while a decoction of Sutherlandia is used to wash wounds and the eyes and to 
reduce fevers, and the infusions from the leaves and stems used to treat cancers, 
fever, diabetes, kidney and liver problems, rheumatism, and stomach ailments 
(Aboyade et al. 2014). However, these traditional tea and decoction dosage forms 
have several disadvantages. Some of the disadvantages include: time and correct 
method needed for preparation, difficulty in controlling the exact dose, short 
duration of effect of the herbal active constituents, and high susceptibility to 
microbial contamination and product degradation (Munodawafa, T. 2012).  
 
Currently, S. frutescens is still one of the commonly used medicinal plants in the 
Western Cape (Van Wyk et al. 2008) but not necessarily in the old traditional 
dosage forms. It is now also sold commercially as solid dosage forms, i.e. tablets 
and capsules, of dried S. frutescens, which can be seen as a solution to some of the 
challenges found with the traditional liquid dosage forms. For instance, solid dosage 
forms could provide greater accuracy in dosing and good pharmaceutical product 
quality and stability, and thus better shelf life (Hefferon, 2012). In addition, 
capsules and tablets containing the freeze dried aqueous extracts (FDAE) could 
provide actions similar to that of the tea dosage form. However, the dried extract 
itself may also have further disadvantages of its own. For instance the dried extract 
powder may not have uniform particle size, adequate flow characteristics and might 
be hygroscopic, all of which may lead to difficulties in the manufacture and poor 
quality of the final product. Therefore, using modified forms, such as phytosomes 
and liposomes, for delivering the S. frutescens, could be a more viable solution. 
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2.6  Drug Delivery Systems. 
A drug delivery system (DDS) is a preparation in which a drug is incorporated in a 
carrier to control the delivery of the drug to the site of action. Examples of DDS 
include liposomes, ethosomes, niosomes and phytosomes, etc. as shown in figure 
2.4. A DDS offers the advantages of delivering drugs, including phytoconstituents, 
at predetermined rate and delivery at the site of action thus minimizing the 
incidence of toxic effects and increasing the bioavailability of the drugs. This is 
possible because in DDS technology, control of the distribution of drug is achieved 
by incorporating the drug in a carrier system or in changing the structure of the drug 
at molecular level (Dhiman, et al 2012). The carrier, firstly, should deliver the drug 
at a rate as needed by the body over the period of treatment and secondly, it should 
deliver the actives of the herbal drug to the relevant site of action (Kataoka, et al 
2001).  The use of an effective DDS can thus make herbal drugs less toxic and also 
enhance their therapeutic effects (Mills, et al 2005).  Therefore, in this study the use 
of two such DDS, viz. liposomes and phytosomes for delivery of herbal products, 
was investigated. 
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Figure 2.4 Drug delivery systems based on herbal formulation adapted from    
(Attama, et al 2012) 
 
2.6.1 Liposomes. 
A liposome, defined as microscopic spherical-shaped vesicle, consists of an internal 
aqueous compartment entrapped by one or multiple concentric lipidic bilayers. The 
liposome’s membrane is composed of natural and/or synthetic lipids, which are 
relatively biocompatible, biodegradable and non-immunogenic material (Laouini, et 
al 2012). This delivery system was first produced in England in the 1960’s, by 
Bangham who was studying phospholipids and blood clotting (Bangham, A. et al 
1967). According to legend, he was experimenting with new laboratory equipment, 
and he observed that phospholipids formed closed multilamellar vesicles 
spontaneously in aqueous solution, an observation which took two years to be fully 
proved (Laouini et al. 2012). Liposomes consist of polar lipids which are 
characterized by having a lipophilic and hydrophilic group on the same molecule, i.e. 
are amphiphilic molecules (Gregoriadis, Florence 1993). Upon interaction with 
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water, the polar lipids self-assemble and form self-organized colloidal particles. A 
cross-section of a liposome (figure 2.5) depicts the hydrophilic heads of the 
amphiphile orienting towards the water compartment while the lipophilic tails orient 
away from the water towards the center of the vesicle, thus forming a bilayer. 
Consequently, water soluble compounds are entrapped in the water compartment and 
lipid soluble compounds aggregate in the lipid section. Uniquely, liposomes can 
encapsulate both hydrophilic and lipophilic materials.  
 
Liposomes have been used to change the pharmacokinetic profile of, not only drugs, 
but also herbs, vitamins and enzymes. Indeed, a variety of herbal liposomal 
formulations has been made and studied. Because of their unique properties 
liposomes are able to enhance the performance of herbal drugs or products by 
increasing or enhancing solubility (Laouini, et al 2012), bioavailability, intracellular 
uptake and in vitro and in vivo stability of the active ingredient as well as alter active 
ingredient pharmacokinetics and bio-distribution (Jaafar-Maalej, et al. 2012). 
Liposomes, as a drug delivery system, can therefor improve the therapeutic activity 
and safety of drugs, mainly by optimally delivering them to their site of action and by 
maintaining therapeutic drug levels for prolonged periods of time.  Liposomes of S. 
frutescens could therefore also have these improved qualities.   
 
2.6.2 Phytosomes. 
Phytosomes are phospholipid-based drug delivery systems that have also been 
found promising for herbal drug delivery. The term phytosome relates to “phyto”, 
which means plant; while “some” means cell-like. Phytosomes are advanced forms 
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of herbal products that are better absorbed and utilized to produce better results than 
conventional herbal extracts (Choudhury, et al 2014). They generally show better 
pharmacokinetic and therapeutic profiles than conventional herbal extracts 
(Sindhumol, et al 2010). 
 
The production of phytosomes is an intricate process. It involves the incorporation 
of phospholipids into standardized herbal extracts and the phytosomes are prepared 
by complexing the poly-phenolic phyto-constituents with phosphatidylcholine   in 
a 1:2 or 1:1 ratio. During this process, a small micro-sphere or cell is produced 
(Gandhi et al. 2012); (figure 2.5).  
 
In comparison to simple herbal extracts, phytosomes are more available and have 
an enhanced capacity to cross the lipid rich biomembranes and finally reaching the 
blood (Amin, et al 2012). Compared to a conventional herbal formulation, a 
phytosome have following advantages. 
 
 It enhances the absorption of lipid insoluble polar phyto-constituents 
administered via oral as well as topical routes leading to better 
bioavailability, 
 Besides acting as a carrier, the phosphatidylcholine used in preparation of 
the phytosome also acts as a hepatoprotective agent hence producing 
synergistic effect if hepatoprotective substances are to be delivered, and 
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 Phytosomes can be used for systemic targeting; thus it is widely used in 
cosmetic technology due to its skin penetration ability and high lipid 
permeability properties. 
 
The phytosome process has been applied successfully to many popular herbal extracts 
(Nilesh et al., 2010) including Ginkgo biloba, grape seed, hawthorn, milk thistle 
(Silybum marianum), green tea (Thea sinensis) and ginseng (Panax ginseng). The 
flavonoid and terpenoid components of these herbal extracts are able to directly bind 
to phosphatidylcholine. Consequently, phytosomes is a particularly exciting new 
advanced modern dosage formulation technology for delivery of herbal products 
containing such phytoconstituents, with better absorption and bioavailability than that 
obtained by conventional herbal extracts, expected. Phytosomes of S. frutescens could 
therefore also have these improved qualities. 
 
 
2.7 Similarities and Differences between Phytosomes and Liposomes. 
Although similar, fundamental differences exist between a phytosome and a 
liposome. Liposomes are formed by mixing phosphatidylcholine with solution of 
water soluble substances in a definite ratio. Figure 2.5 shows phosphatidylcholine 
molecules surrounding the water soluble substance with no chemical bond being 
formed between them. Usually, there are hundreds or even thousands 
of phosphatidylcholine molecules surrounding the water-soluble compound (Saraf 
2010). In phytosome formation, on the contrary, the plant components and the 
phosphatidylcholine actually form a 1:1 or a 2:1 molecular complex depending on 
the plant substance (s) involved. And this leads to the formation of a chemical bond 
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between the plant constituent and lipid which, in turn, increases the lipophilicity, 
rate of absorption and bioavailability of the plant constituent in the phytosomes, 
better than in the case of liposomes. Because of this, the tissue penetrationof drug 
in phytosomes have generally been found to be superior that for liposomes in topical 
and skin care products (Bhattacharya 2009). 
 
Another difference between phytosomes and liposomes is their active drug 
encapsulation efficacies. Phytosomes have a higher drug encapsulation efficacy 
than liposomes. According to Kareparamban, J. et al (2012) this is because the drug 
itself is conjugated (i.e. bound) with lipids when the vesicles are formed, leading to 
higher drug levels in the vesicles and, consequently, phytosomes.  
 
 
Figure 2.5  Similarities and Difference between phytosome and liposome. 
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2.8 Phospholipids Used in Preparation of Liposomes and Phytosomes. 
Phosphoplipids are amphipathic molecules containing a hydrophilic head group and 
hydrophobic hydrocarbon chain with glycerol or sphingomyeline as a backbone 
(figure 2.6) (Thompson 2005). They are found in high levels in all cell membranes 
of living matter and in aqueous solutions can form into a variety of supramolecular 
structures through the hydrophobic interactions of the hydrocarbon chains. The 
amphipathic nature of these molecules in fact gives them the ability to form closed 
concentric bilayers in the presence of water. 
Phospholipids of natural or synthetic origin are used in the production of liposomes. 
Phosphatidylcholine is the most common natural polar phospholipid used and 
lecithin another example of a natural phospholipid while the glycerophospholipids 
are examples of synthetic phospholipids. For this study phosphatidylcholine and 
lecithin, the natural phospholipids were used. 
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Figure 2.6  Structure of phospholipids. 
 
2.8.1 Lecithin.  
Lecithin is a generic term used to designate any group of yellow-brownish fatty 
substances occurring in animal and plant tissues and is manufactured in the liver from 
dietary choline. Lecithins are usually phospholipids composed of phosphoric acid 
with choline, glycerol or other fatty acids, usually glycolipids or triglyceride (i.e. is 
mostly a mixture of glycolipids, triglycerides, and phospholipids). The 
glycerophospholipids in lecithin include phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and 
phosphatidic acid. 
Lecithin has for many years been widely used as a pharmacological agent and food 
supplement. It is most commonly produced by separating and refining of egg yolk 
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and soy bean. Lecithin has low solubility in water; however in aqueous solution its 
phospholipids can form liposome bilayer sheets, micelles or lamellar structures, 
depending on hydration and temperature (Stein, Stein 1969). 
 
2.8.2 Phosphatidylcholine (PC). 
Phosphatidylcholine  is the most common phospholipid used in the preparation of 
liposomes and phytosomes, mainly due to its stability and capacity to act against 
changes in pH (Kulkarn, et al 2011). It is also the most important and common lipid 
found in natural membranes, accounting for 50-90% of the cell membrane 
(Carmona-Ribeiro 2003). In mammals, PCs are synthesized from the diacylglycerol 
(DAG) branch of the phospholipid synthetic pathway. Phosphocholine is 
transferred to carbon-3 via the action of the choline: 1, 2-diacylglycerol choline 
phosphor transferase. This results in a compound that contains a hydrophilic head 
group with a quaternary ammonium moiety choline, which is linked to glycerol via 
a phosphoric ester (Brandl 2001). The permanent positive charge on the choline of 
the head group counteracts the negative charge of the phosphate to give a neutral 
hydrophilic head group (Crowell 1997). Phosphatidylcholine is easily obtained 
from many different sources but most commonly from egg yolk or soybeans 
through mechanical or chemical extraction using hexane.  Phosphatidylcholine is 
such a major component of lecithin that in some contexts the terms are sometimes 
used as synonyms. However, lecithin extracts actually consist of a mixture of 
phosphatidylcholine and other compounds (Adeyeye 2013). 
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2.9 Preparation Methods for Phospholipid-based Drug Delivery Systems 
(DDS). 
There are three classical methods of preparation for phospholipid-based drug 
delivery systems. The difference between the various methods is usually based on 
the way in which the lipids are dried of organic solvents and then re-dispersed in 
aqueous media. These steps are performed individually, as described in the 
following sections. 
2.9.1 Hydration of a Thin Lipid Film Method  
This is the method which was originally used for liposome production (Bangham, 
A. et al 1967). In this method, the mixture of phospholipid was dissolved in organic 
solvent for preparation of liposomes, while in the case of phytosomes the lipid phase 
was dissolved in organic solvent containing the drug substance. Then, the organic 
solvent was removed by means of evaporation (under reduced pressure using a 
Rotary Evaporator). Finally, the dry lipid film deposited on wall of the flask was 
hydrated by adding an aqueous buffer solution under agitation and at temperature 
above the lipid transition temperature. This resulted in phospholipids dispersed in 
the aqueous buffer yielding multilamellar liposomes and phytosomes (MLVs) 
which are heterogeneous in both size (1–5 µm diameter) and shape. This method is 
widely used and easy to implement. However, to solve the heterogenous size and 
shape problem new techniques, such as sonication for small unilamellar vesicle 
(SUV) formation or extrusion through polycarbonate filters for large unilamellar 
vesicles (LUVs), were introduced to produce smaller and more uniformly sized 
populations of vesicles (Picard et al. 1999). 
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2.9.2 The Reverse-Phase Evaporation (REV) Technique. 
In this method a lipidic film is also prepared by evaporating the organic solvent 
under reduced pressure. The system is then purged with nitrogen and the lipids re-
dissolved in a second organic phase, which usually consists of diethyl ether and/or 
isopropyl ether. Thereafter oligolamellar vesicles are formed when an aqueous 
buffer is introduced into this mixture. The organic solvent is subsequently removed 
and the system is maintained under continuous nitrogen. 
These vesicles typically have aqueous volume to lipid ratios that are 30 times higher 
than that of sonicated preparations and 4 times higher than multilamellar vesicles. 
Most importantly, a substantial fraction of the aqueous phase (up to 62% at low salt 
concentrations) is entrapped within the vesicles, thus encapsulating even large 
macromolecular assemblies with high efficiency (Szoka, Papahadjopoulos 1978). 
 
2.9.3 The Solvent (Ether or Ethanol) Injection Technique. 
The solvent injection methods involve the dissolution of the lipid into an organic 
phase (ethanol or ether), followed by the injection of the lipid solution into aqueous 
media to form liposomes. The ethanol injection method was first described in 1973 
(Wagner, Vorauer-Uhl and Katinger 2002) and the main relevance of the ethanol 
injection method resides in the observation that a narrow size distribution of small 
liposomes (under 100 nm in size) can be obtained, in one step, by simply injecting 
an ethanolic lipid solution into water without extrusion or sonication. The ether 
injection method differs from the ethanol injection method in that the ether is 
immiscible with the aqueous phase, and the latter heated to remove the solvent from 
the liposomal product. Specifically, the method involves injection of ether-lipid 
solutions into aqueous phases warmed at above the boiling point of the ether. The 
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ether vaporizes upon contacting the aqueous phase, and the dispersed lipid forms 
into, primarily, unilamellar liposomes. An advantage of the ether injection method, 
compared to the ethanol injection method, is that this removal of the solvent from 
the product enables the process to be run for extended periods forming a 
concentrated liposomal product with high entrapment efficiencies. 
For the present study, the thin film hydration technique was chosen because of its 
simplicity, as well as the fact that it does not introduce any impurities that can affect 
the phase behavior and release properties of liposomes, as may occur in the case of 
the reverse phase evaporation method (Akrachalanont, P. 2008). 
 
2.10 Classification of Drug Delivery Systems Based on Size. 
Liposomes and phytosomes vary in size usually, depending on the method of 
production,  ranging from 20 nm upwards  and may be composed of one or many 
concentric layers, each with a thickness of roughly 4 nm (figure 2.7)  (Barbe et al. 
2004). Sonication is the most extensively used method for preparation of liposomes 
in a size range of 200 nm and above. Here the multilamellar vesicles (MLVs) are 
transformed into SUVs (small unilamellar vesicles) by either probe or bath 
sonication (Lichtenberg, Barenholz 1988). 
For optimal therapeutic use and administration route considerations the size of 
novel drug systems is an important parameter since size will influence the rate of 
clearance of the DDS by the reticular endothelial system and its ability to remain in 
the blood vessels after introduction into the human body. The size also influences 
the drug loading capacity and the bioavailability of the DDS (Saraf 2010). 
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Therefore, novel drug delivery systems are typically classified on the basis of their 
size and number of bilayers as shown in Table 2.2. 
 
Table 2.2:  Size specification of vesicular novel drug delivery systems  
Abbreviation Type of vesicles Size Specification 
MLV Multilamellar large vesicle > 0.5m 
OLV Oligolamellar vesicles- 0.1 - 1m 
UV Unilamellar vesicles No fixed size range 
 (20 nm - >1 m)  
SUV Small Unilamellar vesicles- 20-100 nm 
MUV Medium sized Unilamellar 
vesicles 
40-80 nm 
LUV Large Unilamellar vesicles > 100-200 nm 
GUV Giant Unilamellar vesicles- > 1m 
MV Multivesicular vesicles- 1m 
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Figure 2.7  Classification of drug delivery systems based on size (Laouini et 
al. 2012)  
  
2.11 Novel Drug Delivery System Stability. 
The stability of a DDS, such as a liposome or phytosome, is another important, and 
sometimes complex, pharmaceutical characteristic that must be determined and 
known. Novel drug delivery system stability entails both physical and chemical 
stability.  
 
The physical stability of a DDS is mostly assessed by determining the size and 
charge, and the lipid to active agent ratio used for, the DDS. The charge of a DDS 
may be measured in terms of Zeta potential (i.e. the difference in electric potential 
between the dispersion medium and the stationary layer of fluid attached to 
a dispersed particle) and a low Zeta potential ( i.e. in the range between +30mv to -
30mv) results in physical instability of such a nano-formulation (Averineni et al., 
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2012). The charge of the liposome surface should be considered if the possibility of 
aggregation is considered. The ability of liposomes and phytosomes to maintain 
their superficial charge for long durations during storage adds to the high physical 
stability of the formulation and shelf life. Thus, cationic liposomes can be stable at 
4°C for long periods of time, if properly sterilized (Tikshdeep, C. et al. 2012). 
Finally, while the lipid to active agent ratio used also affects the physical stability 
of a DDS, phytosomes also have a better stability profile due to the formation of 
chemical bonds between phosphatidylcholine molecules and the phytoconstituents 
(Kareparamban, J. et al 2012).  
 
Ensuring the chemical stability of liposomes and phytosomes mainly entails the 
prevention of both the hydrolysis of ester bonds in the phospholipids bilayers and 
the oxidation of unsaturated sites in the lipid chain, i.e. their chemical instability 
can occur through oxidative and hydrolytic degradation pathways (Nikolelis et al. 
1996). Usually oxidation in liposomes occurs in the unsaturated fatty acyl chain-
carrying phospholipids with the chains being oxidised via a free radical chain 
mechanism in the absence of particular oxidants. In addition, the ester groups of the 
phospholipids can be hydrolyzed in the presence of water, producing 
lysophospholipids, a high concentration of which commonly leads to an increased 
permeability of the lipid bilayer and a destabilization of the system (de Araújo 
Lopes, et al. 2013). Chemical instability can thus lead to physical instability or 
leakage of encapsulated drug from the bilayers and fusion and, finally, aggregation 
of vesicles.  
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Finally, several approaches can be taken to increase the physical and chemical 
stability of liposomes, including the following precautions (Kaur, et al 2013):  
 To reduce oxidation, novel drug delivery systems can be stored at low 
temperatures, protected from light and antioxidants such as -tocopherol 
and butyl hydroxy toluene added. More so, processing with fresh, purified 
lipids and solvents also helps to reduce oxidation. 
 Avoidance of high temperature and excessive shear forces.  
 Maintenance of low oxygen potential (i.e. nitrogen purging) by working 
under nitrogen or argon thereby minimizing the oxidation of lipids during 
preparation. 
 Use of antioxidant or metal chelators (as additional excipients or during 
preparation). 
 The hydrolysis of ester bonds can be reduced by optimising the pH, 
temperature, ionic strength, chain length and the amount of cholesterol 
incorporated into the bilayer during (liposome) preparation (Rosen, 
Kunjappu 2012). 
 Formulating a preparation having or at neutral pH. 
 
Using these strategies DDS with increased or optimal physical and chemical 
stability can be obtained.  
 
2.12 Characterization of Liposomes and Phytosomes  
The characterization of novel drug delivery systems such as liposomes and 
phytosomes can be divided into three parts: physical, chemical and biological 
characterization.  
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Physical characterization mainly consists of evaluating the size, shape, surface 
features, lamellarity, phase behaviors and drug release profile of the liposome or 
phytosome.  A variety of useful parameters can be determined using the methods 
and instruments indicated in table 2.3. 
Table 2.3:  Physical parameters and instrumental methods of analysis for 
characterization of novel drug delivery systems (e.g. liposomes and 
phytosomes) 
 
  
On the other hand, the chemical characterization of liposomes is mostly focused on 
establishing the level and purity of the various liposomal constituents. This includes 
the quantification of phospholipids, level of lipid oxidation, pH and the percentage 
of encapsulated drug (active constituent). These characteristics can be determined 
using the methods and instruments indicated in table 2.4. 
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Table 2.4: Parameters and methods used for chemical characterization of lipid-
based drug delivery systems. 
 
Finally, biological characterization of DDS is also important and must be done to 
establish the safety profiles and suitability of the DDS formulation for therapeutic 
application. However, by just taking the physical and chemical characteristics into 
account, a reasonably fair idea of the final in vitro and in vivo behavior of a new 
DDS can already be obtained. 
 
2.13 Drug Release Profile of Drug Delivery System. 
Finally, one of the most important characteristics of a drug delivery system is its 
ability to release drug from the carrier. There are numerous factors that affect drug 
release, e.g. drug solubility, desorption kinetics of adsorbed drug, diffusion of drug 
through the nanoparticles, nanoparticle degradation, and the combination of 
degradation and diffusion (Lockman, P. R., 2012).  Typically, in conventional 
nanospheres, the drug is distributed uniformly and diffusion or erosion of the matrix 
causes the drug to be released. If diffusion happens faster than matrix erosion, the 
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release mechanism is controlled by diffusion (Siegel, R. A., and Rathbone, M. J. 
2012). 
Kinetic experiments are usually done to determine the release characteristics of a 
DDS and such kinetic experiments are carried out respecting/maintaining sink 
conditions in the receptor compartment (Ammoury, et al 1990). Samples are then 
taken at various time intervals and assayed for the drug by HPLC, spectrophotometry 
or any other convenient method. The sample volume is normally replaced with fresh 
dissolution medium so that the volume of the receptor compartment remains constant. 
Every kinetic experiment is performed in triplicate and the average values are taken 
to establish the release profile of the drug from the liposome and phytosomes 
suspension (Ammoury, et al 1990). 
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CHAPTER THREE 
Plan of Work 
 
3.1 Introduction 
In this chapter, the specific objectives, hypotheses and study approach for this study 
are described. 
 
3.2  Objectives 
The overall aim of the study was to establish which of phytosomes or liposomes are 
the better dosage form for delivery of flavonoid actives from the freeze-dried 
aqueous extract of Sutherlandia frutescens. 
The specific objectives of the study were to: 
1.  Formulate and prepare phytosomes and liposomes containing Sutherlandia 
frutescens freeze dried aqueous extract (FDAE), 
2.  Determine and compare the physical characteristics i.e., particle shape, size, 
size distribution (in terms of polydispersity index) and stability (in terms of 
zeta potential) of the Sutherlandia phytosomes and liposomes, 
3. Determine the extent of encapsulation of the Sutherlandia flavonoids in these 
phytosomes versus liposomes, and 
4.   Compare the flavonoid release profiles from the Sutherlandia containing 
phytosomes versus liposomes. 
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3.3 Hypotheses 
It was hypothesized that: 
1. Synthesized S. frutescens phytosomes will have a higher encapsulation 
efficiency (i.e. Sutherlandia flavonoid content), than  the synthesized S. 
frutescens liposomes, i.e. 
EE%:   EE% Phytosomes > EE% Liposomes 
                                 
Where the encapsulation efficacy (EE %) is given by the following equation. 
EE%     =                          X100  
 
And Ctotal are the relative amounts (i.e. peak area under the curve of sutherlandins 
A to D) of individual flavonoid in the starting Sutherlandia FDAE solution and Cfree 
the concentration in the supernatant after separation of the liposomes or 
phytosomes.  
  
2. At both gastric and intestinal fluid pH, the amount of flavonoid glycosides 
(i.e. sutherlandins A to D) released from the S. frutescens-containing 
liposomes will be greater than that for the phytosomes, i.e.: 
 
 
 
 
 
Ctotal – Cfree 
Ctotal 
  
 
 
 
 
38 
 
 
 
pH 1.2 
 
pH 6.8 
[Suth.A] Liposomes   > [Suth. A]Phytosomes [Suth.A]Liposomes > [Suth. A]Phytosomes 
[Suth.B]Liposomes > [Suth. B]Phytosomes [Suth.B]Liposomes > [Suth. B]Phytosomes 
[Suth.C]Liposomes > [Suth. C]Phytosomes [Suth.C]Liposomes > [Suth. C]Phytosomes 
[Suth.D]Liposomes > [Suth. D]Phytosomes [Suth.D]Liposomes > [Suth. D]Phytosomes 
 
Where [Suth A, B, C, or D] Liposomes are the relative amount of sutherlandin A. 
B, C or D in the liposomes. And [Suth A, B, C, or D]Phytosomes are relative 
amount of sutherlandin A. B, C or D in the phytosomes. 
 
The drug release profile (i.e. % released over time) was determined using the 
following equation to calculate the percentage released at each time point. 
 
Drug release (%)  =  X100 
 
3.4 Study approach and methods 
To achieve the above objectives, the following were done. 
1. Preparation of S. frutescens freeze dried aqueous extract liposomes and 
phytosomes. 
Amount of drug released at specified time point  
Amount of drug loaded in to nano particle 
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2. Characterization of particle size, shape and stability and extent of 
encapsulation of S. frutescens in phytosomes versus liposomes 
3. Determination of release profile of the flavonoids contained in S. frutescens 
phytosomes versus liposomes. 
3.4.1 Preparation of liposomes and phytosomes of S. frutescens freeze dried 
aqueous extract.  
For this study, the thin film hydration technique was chosen to prepare the liposomes 
and phytosomes because of its simplicity as well as the fact that it does not introduce 
any impurities that can affect the phase behavior and release properties of liposomes, 
as may occur in the case of the reverse phase evaporation method or detergent dialysis 
methods (Liang, et al 2005). 
 The method involved mixing lipid compositions in an organic solvent to ensure a 
homogeneous mixture of lipids with or without the inclusion of hydrophilic molecules 
for the formation of a dry film. The dry film of lipids would then be deposited onto the 
wall of a round-bottom flask in a rotary evaporator at a temperature above the lipid’s 
phase transition temperature. Thereafter, the thin film in the round bottom flask was 
to be hydrated by adding a buffer solution containing the hydrophilic drugs or plant 
compounds to be encapsulated. This method usually yielded a heterogeneous 
population of multilamellar liposomes (MLVs) in a size range of 200nm and above, 
therefore liposome and phytosome size reduction techniques, such as sonication for 
SUVs formation was further  required (Laouini et al. 2012) and to be performed in this 
study. 
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3.4.2 Characterization of the S. frutescens phytosomes and liposomes.  
In order to assess the quality of the liposomes or phytosomes and to obtain quantitative 
measures that allow comparison of differences between the liposomes and 
phytosomes, various parameters should be monitored. For drug delivery system 
applications in analytical and bio-analytical fields, the main characteristics to monitor 
usually include the particle shape, average mean diameter, size distribution (i.e. 
polydispersity index) and stability and encapsulation efficiency  (Pathak, Thassu 
2009), and these characteristics were consequently determined for the S. frutescens 
liposomes and phytosomes in this study. 
 
Specifically, the average size and size distribution of liposomes and phytosomes were 
measured by Photon Correlation Spectroscopy (PCS) based on dynamic light 
scattering (DLS) technology.  Advantages of using this method include its sensitivity, 
minimal sample requirement and wide range of applications.(Edwards, Baeumner 
2006). For the morphology analysis, the pellet of the liposomes and phytosomes were 
examined photographically with a scanning electron microscope, a standard procedure 
to determine the shape and size of the particles. 
 
The zeta potential of a particle, which is the overall charge that a particle acquires in a 
particular medium, is another physical property which is exhibited by any particle in 
suspension and is a very good index of the interaction magnitude between colloidal 
particles (Wang et al. 2006). If the particles have low zeta potential values, then there 
will be no force to prevent the particles from aggregating and particle suspensions with 
zeta potentials > +30 mV or < −30 mV are normally considered stable (Lee, Lee & 
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Jeon 2007). This technique was therefore also used to compare the stability of the 
liposome versus phytosomes particles in the present study. 
 
Finally, the prepared liposomes and phytosomes would contain a mixture of 
encapsulated and un-encapsulated freeze-dried aqueous extract of S. frutescens (drug 
fractions). For this study the glycosides Sutherlandin A to D was chosen as active 
marker compounds representing the S. frutescens flavonoids, especially due to their 
known presence in the S. frutescens FDAE and because their presence and levels 
would be representative of changes or differences in the active components of the 
medicinal plant in the different forms and /or under different conditions. The 
encapsulation efficiencies of the different forms was also to be compared and the first 
step required for this determination was the effective separation of the encapsulated 
drug (i.e. that within the carrier) and the free drug (i.e. in FDAE). For this 
centrifugation was to be used. The latter is a method that separates the material based 
on the difference in mass of the drug loaded liposomes or phytosomes and the free 
drug. Thus the drug loaded liposomes or phytosomes would be in the pellet, while the 
free drug (i.e. Sutherlandin A to D) was in the supernatant. And finally, for the 
encapsulation efficiency comparison, the free drug in the various fractions had to be 
quantified and for this an HPLC assay was used (because using a plate reader and non-
specific UV detection method for this purpose did not proof successful in  this study).  
This HPLC assay had to be developed and validated –see 3.4.3. 
 
3.4.3  Determination of the drug release profile of S. frutescens liposomes 
versus phytosomes. 
The purpose of the drug release profile study was to determine and compare the 
amounts of flavonoids (as active drug marker compounds) the S. frutescens liposomes 
 
 
 
 
42 
 
and phytosomes contained and for this the HPLC assay was used. This is a commonly 
used and sensitive technique for the assay of flavonoids in plant samples. The latter 
assay was also used because of its ability to separate and quantitate multiple 
components present in plant matrices. 
 
To determine the drug release profiles two different buffer solutions were used to 
mimic some of the various physiological parts of the gastrointestinal tract. The pH 
1.2 medium was used to represent the gastric condition, while pH 6.8 the conditions 
in the small intestine. Furthermore, samples were taken at specific time intervals (i.e. 
5, 15, 30, 60, 90, 120 minutes) to provide a drug release over time profile for both the 
liposomes and phytosomes which could then be compared using the parameters, 
AR120 (%)   i.e. average amount released at 120 min, RAR50 i.e. time of the 50 % amount 
released and f2, the similarity factor (Martinez, Amidon 2002). The latter, in 
particular, is a standard parameter used for such comparison purposes. 
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CHAPTER FOUR 
Preparation and characterization of S. frutescens liposomes and 
phytosomes 
 
4.1 Introduction 
One major aim of this study was to prepare improved active phytopharmaeutical 
(i.e. API) forms of S. frutescens. Specifically, liposomes and phytosomes of the 
freeze-dried aqueous extract of S. frutescens were to be prepared. In this chapter the 
materials, equipment and unique methodology used to prepare and characterise the 
liposomes and phytosomes of S. frutescens are firstly described.  In addition to the 
freeze-dried extract of S. frutescens, liposomes and phytosomes of quercetin and 
rutin, as marker aglycone and glycoside flavonoids, respectively, were also 
prepared and characterised. As part of the characterisation the encapsulation 
efficiency of the liposomes and phytosomes were determined. For this an HPLC 
assay was required and the development and validation of the assay used is 
described.  Finally, the results obtained from all these assessments are presented 
and discussed.  
 
4.2 Materials 
 4.2.1  Chemicals and reagents. 
The following chemicals, reagents and equipment were used. 
Acetonitrile (HPLC grade, Burdick and Jackson®, USA); methanol and 
chloroform (analytical grade, AR Saarchem, Merck Chemicals, PTY Ltd); 
hydrochloric acid 32% (analytical grade, AR Saarchem, Merck Chemicals, PTY 
Ltd); formic acid 99% (analytical grade, KIMIX Chemicals & laboratory 
suppliers, USA); phospholipids (Lecithin powder, Warren Chemical, Germany) 
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and L-α-phosphatidylcholine (Avanti Polar Lipids. USA); Sutherlandia frutescens 
PE (freeze dried aqueous extract (FDAE),BN E62265, see appendix 1, Afriplex Pty, 
Paarl, South Africa);  rutin and quercetin di-hydrate (Sigma Aldrich, Germany);  
sutherlandin A, B, C and, D  (isolated at School of Pharmacy, UWC (see O. 
Mbamalu et al., 2015))  Triton x100 (Sigma Aldrich, Germany); distilled water 
(prepared using a Purite Select Analyst HP water purification system); Phosphate 
Buffer Solution of pH 7.4 (Lonza B-4800, Verviers, Belgium). 
 
4.2.2  Equipment and instruments 
The following equipment and instruments were used. 
High Performance Liquid Chromatography (HPLC) System (An Agilent 
HPLC system 1200 series consisting of a G1311A Quaternary Pump, a G1322A 
Degasser, a G1315B Diode-array detector and a G1329A Auto Sampler with, 
Agilent ChemStation software); C18 reverse phase column (Phenomenex Luna® 
C18 column, 5μm particle size and column size of 250 × 4.6 mm, Puerto Rico, USA); 
2cm LC-18 guard column (Phenomenex   2cm, Torrance, CA, USA). 
  
Rotor evaporator (V- 700/710 (BUCHI, Switzerland); pH meter (Model PL-
700PV, Taipei, Taiwan); ultra-sonic bath (Model 702 Voltage 2030v, 100W, 
LABOTEC, South Africa); sputter coater (K550X Emitech, England); weighing 
balance (AR 2140, 210g United Scientific Ltd, Ohaus Corp. Pine Brook, NJ, USA); 
ultracentrifuge (Beckman Coulter Optima L-80, Beckman, USA); vortex mixer 
(Vortex-2G-560E, Scientific Industries, Inc. Bohemia, N.Y 11716 USA); Zetasizer 
(Nano series, Malvern instrument, UK); Zetasizer software 7.10 (Nano series, 
Malvern, UK); Disposable cuvettes DTS0012 (Nano series, Malvern, UK); 
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Disposable flooded capillary cell DTS1070 (Nano series, Malvern, UK); non-
sterile syringe filter (0.45micron size, Pall life Sciences, USA); parafilm M 
sealing film (Code: 701605, length 38m, Merck Chemicals, PTY Ltd); Millipore 
centrifuge tube 50 (91015, polypropylene, conical base 50ml, TPP, Switzerland).  
4.3 Methods 
4.3.1 Preparation of liposomes. 
The thin film hydration method (Samad, Sultana and Aqil 2007) was used and the 
steps for the liposome preparation are summarized in figure 4.1.   
For the  S. frutescens liposomes, 600 mg lecithin (i.e. lipid phase) was mixed and 
dissolved in 20 ml chloroform for 10 minutes in a 50 ml Millipore centrifuge tube. 
The resultant clear phospholipid solution was transferred to a round bottom flask, 
the latter attached to a rotatory evaporator and the solution evaporated to dryness at 
60 oC and 50 rpm. A thin lipid film was obtained. For the hydration phase, 200 mg 
S. frutescens was dissolved in 20 ml PBS pH 7.4 kept at 50 0C i.e. above the phase 
transition temperature (Tm) of the lipid.  One milliliter of this hydration solution 
was taken for HPLC analysis of the total amount of flavonoids it contain (i.e. Atotal, 
see section 4.3.8) while the rest was then added to the thin lipid film, the mixture in 
the flask vigorously shaken by hand and vortexed for 20 min and then cooled down 
in fridge for 30 mins. Thereafter, the liposome suspension was vortexed for a further 
30 mins. To reduce the size of (i.e. down size) the liposomes, the sonication method 
was used - see section 4.3.3.  
 
This same method of liposome preparation was also used to prepare the liposomes 
of the pure compounds, rutin and quercetin, except that in this case 20 mg of the 
respective flavonoids and 60 mg of the lecithin was used.  
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Figure 4.1 Schematic for the preparation of liposomes  
 
 
4.3.2 Preparation of phytosomes.  
For the phytosome preparation the same method was used and is summarized in 
figure 4.2.  In this case, 200 mg of FDAE and 400 mg of phosphatidylcholine i.e. 
lipid phase, was first mixed and dissolved in 20 ml of chloroform for 10 min in 50 
ml Millipore centrifuge tube and the resultant mixture containing the 
phosphatidylcholine - S. frutescens FDAE complex evaporated to dryness on a 
rotary evaporator at 60 0C and 50 rpm. Thereafter, the thin lipid film loaded with 
crude extract obtained,  was hydrated with 20 ml PBS pH 7.4 at 50 0C, a temperature 
above the phase transition temperature (Tm) of the lipid, the mixture (i.e. hydrated 
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solution) vigorously shaken by hand and vortexed for 20 min and then cooled down 
in a fridge for 30 minutes. The resultant phytosome suspension was vortexed for a 
further 30 minutes, and to down size the phytosomes, the suspension was sonicated 
for 45 minutes – see section 4.3.3. 
 
This same method was also used to prepare the phytosomes of the pure compounds, 
rutin and quercetin, except that in this case 20 mg of the respective flavonoids and 
40 mg of the phosphatidylcholine was used.  
 
 
Figure 4.2 Schematic for the preparation of phytosomes  
 
4.3.3  Reduction of size of liposomes and phytosomes. 
The reduction of size of the liposomes and phytosomes were effected using the 
sonication technique (Huang et al. 2010). For the liposomes, the liposome 
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suspension (E) described in section 4.3.1 was transferred to a round bottom flask, 
the latter placed in the sonicator bath and sonicated for 1h at 40 0C. For the 
phytosomes, the thin film layer was hydrated with PBS pH 7.4 at 50 0C, and also 
sonicated for 1h at 40 0C. After the size reduction process, the liposome and 
phytosome suspensions were centrifuged for 2 hours at 4 0C and 30,000 rpm using 
an ultracentrifuge, to separate unwanted particles leached during the sonication 
process. Finally, the supernatant was decanted and transferred to a vial for HPLC 
analysis. The remaining pellet was weighed and stored in its test tube at – 20 °C in 
freezer until further analysis, i.e. size analysis and distribution by PCS and drug 
content analysis by HPLC, etc.     
 
4.3.4  Scanning Electron Microscopy (SEM).  
To determine the shape and size of the liposomes and phytosomes high resolution 
scanning electron microscopy (HR-SEM) was used. After ultra-centrifugation (E) 
the supernatant was removed and the pellet rehydrated and used for SEM analysis. 
A drop of sonicated liposomes or phytosomes was placed on carbon adhesive tape; 
the latter applied onto an aluminium stub and then dried completely in a fume hood. 
Thereafter the dried liposome or phytosome nanoparticles were coated with gold 
palladium using an Emitech K550X (England) sputter coater and viewed using a 
Auriga F50 HR-Scanning Electron Microscope with working distances of 6.6, 6.7 
and 6.8 mm and accelerating voltage of 5 kv as the instrument operating parameters. 
Photographs of the particles were taken within a range of 5-50 kx and displayed the 
shape and size characteristics of liposomes and phytosomes. 
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4.3.5 Size analysis and distribution of liposomes and phytosomes. 
For the size analysis of the liposome and phytosome vesicles the Photon Correlation 
Spectroscopy (PCS) technique, one that measures the size of particles in the 
nanometre range, was used to investigate and confirm the vesicular structure of the 
particles obtained after hydration. Polydispersity of the vesicle size is observed by 
this technique which gives an idea of the distribution of various sizes of vesicular 
structures (Goll et al. 1982).  In addition, a Zetasizer, i.e. an instrument which uses 
Brownian motion of particles to reflect their size (Dobrovolskaia et al. 2009), was 
also used for the size and size distribution analysis. In this case, 1 ml of liposome 
and phytosome suspensions, prepared as described in 4.3.1 and 4.3.2, were placed 
in a cuvette (V) in the Zetasizer and the software facilitated instrument recorded 
readings obtained.  Size and size distribution were presented by the Z-average and 
polydispersity index (PI) values, respectively. In addition, the dynamic light 
scattering (DLS) technique, which more accurately measures size of particles in the 
micrometer size range than particles in the submicron range, was also used. Finally, 
all the data were used to compare the size and size distribution of the flavonoid-
containing liposomes versus that for the phytosomes.  
 
 
 
4.3.6 Analysis of stability of liposomes and phytosomes. 
A potential exists between the particle surface and the dispersing liquid, which is 
called the Zeta potential and can be used for measuring the stability of particles 
(Jiang, et al 2003). 
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For this study measurement of the Zeta potential (ZP) of the liposomes and 
phytosomes were carried out using the Zetasizer instrument. Before analysis, the 
disposable folded capillary cell of the instrument was rinsed with distilled water 
and then 700 μl of the liposome and phytosome suspensions was separately added 
to the  disposable zeta cell,  the temperature set at 25°C and the measurements 
conducted at an angle of 173° for ten cycles at a voltage of 4 mv. The intensity-
weighted mean value of three Zeta potential measurements was taken. If the 
particles had low zeta potential values; there would be no force to prevent the 
particles from aggregating. Therefore, particle suspensions with zeta potentials > 
+30 mV or < −30 mV are normally considered stable (Lee, Lee & Jeon 2007). This 
technique was therefore used to compare the stability of the liposome versus 
phytosomes particles. 
  
4.3.7 Development and validation of HPLC assay for S. frutescens 
flavonoids. 
 
A validated HPLC method, as described below, was used for analysis of the 
flavonoid content of the liposomes and phytosomes prepared in this study. 
 
4.3.7.1  HPLC system and conditions 
 
The HPLC system used for the acquisition of chromatograms and UV spectra was 
an Agilent 1200 series system with diode array detection (DAD), and data 
acquisition and processing was carried out using the OpenLAB™ CDS 
ChemStation Edition software (Agilent Technologies, Palo Alto, CA, USA).  
For chromatographic separation of the flavonoid compounds a reverse phase 
Phenomenex Luna® C18 column (25 cm x 4.6 mm, 5 µm i.d.) with a compatible 
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guard column, both maintained at 45°C, were used. The mobile phase, consisting 
of water (0.01 % formic acid) (A) and acetonitrile (0.01 % formic acid) (B), was 
filtered through a 0.45 µm filter and degassed prior to use. The flow rate of the 
mobile phase was maintained at 0.8 ml/min, the injection volume was twenty 
microliters, the wavelength for analysis and detection 370 nm, and peaks were 
separated  by gradient elution with solvents A  and B as follows: from 0 to 1 minutes 
82% (A) and 18% (B); 15 minutes 75% (A) and 25% (B); 20 minutes 65% (A) and 
35% of (B); 25 minutes 40% (A) and 60 % of (B); 26 to 35 minutes 82% of (A) and 
18% of (B). The isolated compounds were identified based on their retention times 
(tR) and UV-spectra.  
 
4.3.7.2  Validation 
 
Six flavonoids (i.e. five glycosides, Sutherlandins A to D and rutin, and aglycone 
quercetin) were selected as marker compounds. An HPLC assay was developed, 
validated and used for the quantification of various flavonoids in S. frutescens 
materials in an earlier study (Mbamalu et al., 2015) and the same assay was now 
used for the present study and the following parameters determined to validate the 
HPLC assay according to the ICH (1997) guidelines.  
 
Assay stock solutions were prepared by dissolving specific amounts of the reference 
standards in methanol: water (50:50) and diluting them further to obtain calibration 
and quality control sample solutions in concentration ranges between 0.5 and 2 mM 
for the various marker compounds.   
To establish the linear concentration range for each marker compound a calibration 
curve was developed by injecting 20 µl samples of reference standard solution into 
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the HPLC, measuring the peak area and plotting concentration versus peak area. 
Triplicate samples over a six sample concentration range were used to establish the 
curve.  The linearity of the calibration curve for each of the reference standards was 
assessed by linear regression analysis of these plots of peak area against concentration 
using GraphPad PrismTM version 6.0.  
 
 For the Limit of Detection (LOD) and Limit of Quantification (LOQ) determinations, 
the peak area was used as the signal response and the mean baseline noise taken as = 
0.4 mAU (n = 3). The LOD and LOQ were determined using an analyte response 3 
and 10 times that of the noise (i.e. signal to noise ratio of 3:1 and 10:1), respectively, 
and the mean baseline noise = 0.4 mAU; n = 3. The percentage bias was determined 
as the difference between the mean concentration measured and the prepared 
concentrations as a percentage of the prepared concentration using n = 6 samples. 
The precision of the analytical method was determined by assaying 6 spiked samples 
at the lower and upper limits of the concentration range studied for each of the marker 
compounds. The accuracy of the method was determined from the mean 
concentrations obtained for the replicates and the percentage difference. The relative 
standard deviations (% RSD) were then calculated for the reference standard samples 
at the lower and upper limits of the concentration range. 
Finally, system suitability parameters were calculated from the chromatograms 
obtained for each of the reference standards during the studies using the Agilent 
ChemStation software. 
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4.3.7.3 Quantification of levels of marker compounds in S frutescens 
(extract)  
 
In this study liposomes and phytosomes of S frutescens were made and the levels of 
flavonoid marker compounds in the S frutescens extract used needed to be 
determined. For the latter a modification of the method described by Avula et al. 
(2010) was used (as further described by O. Mbamalu et al, (2015)). 
 
Briefly, about 100 mg of accurately weighed FDAE S. frutescens material was added 
to 2 ml of 50 % aqueous methanol, the mixture sonicated for 30 minutes and then 
centrifuged at 3500 rpm for 15 minutes. The extraction procedure was repeated thrice, 
the respective supernatants combined, the final volume adjusted to 8 ml with 50% 
aqueous methanol and mixed thoroughly. Prior to injection into the HPLC, 
appropriate dilutions were made, and the final solutions filtered using a 0.45 µm nylon 
membrane filter. The first 1.0 ml of filtrate was discarded and the remaining volume 
collected in an LC sample vial. Twenty microliters of each sample solution was 
analysed using the validated HPLC method previously described under section 4.7, 
and the peak areas of the flavonoids of interest noted. Triplicate samples of the FDAE 
solutions were assayed and the average peak areas calculated to quantify and compare 
flavonoid content in the S. frutescens extract. Data was presented as average 
percentage content (i.e. mg flavonoid * 100 /mg plant material) ± SD (n = 3). 
4.3.8  Determination of drug entrapment efficiency of liposomes and 
phytosomes. 
 
The efficiency (EE) of the entrapment of S. frutescens extract (i.e. the API) or rutin 
or quercetin in the phytosomes and liposomes were determined after HPLC analysis 
of samples of the free drug (i.e. Atotal in FDAE hydrated solutions (see section 4.3.1) 
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and the encapsulated (loaded) drug within the carrier (liposomes and phytosomes). 
For the latter, centrifugation was used to separate the encapsulated API and free 
drug (i.e. API) (Fan et al. 2007) and the liposomes and phytosomes analysed were 
those prepared as described in sections 4.3.1 and 4.3.2.  
 
Briefly, the liposome and phytosome suspensions obtained were centrifuged at 4 0C 
and 30,000 rpm, for 2 hours. Thereafter the clear supernatant were collected, filtered 
(0.45 micron filter), transferred to HPLC vials and aliquots of the latter analyzed to 
give the levels of free i.e. un-encapsulated API (S. frutescens extract, or rutin or 
quercetin) (Afree). Similarly, samples of the S. frutescens and flavonoid hydration 
solutions (see section 4.3.1) were analysed to give the total API levels  
 
The entrapment efficacy was then determined using the following equation: 
 
EE %  =  (Atotal   – Afree / Atotal)*100    
   
where Atotal is  the relative amount (i.e. area under chromatographic peaks) of 
individual flavonoid (i.e. sutherlandins A to D or rutin or quercetin ) in the 
chromatograms of starting Sutherlandia FDAE, or rutin or quercetin solutions and 
Afree  the relative amount of these flavonoids in the supernatant after separation of 
the liposomes or phytosomes. These assays were done in triplicate (n = 3) and the 
EE (%) results for the liposomes and phytosomes compared using GraphPad Prism 
and ANOVA.   
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4.4 Results and discussion 
 
4.4.1 Preparation of liposomes and phytosomes  
Both liposomes and phytosomes were successfully prepared using the thin film 
hydration method. This method requires the formation of a thin film on the surface 
of a round bottom flask, a hydration step, hand shaking and vortexing, all at a 
temperature above the phase transition temperature (Tm). The yield of S. frutescens 
phytosomes was 53 %, while that for the S. frutescens liposomes was only 32 % 
(i.e. approximately 40 % lower than that for phytosomes).  
It took 60 minutes to obtain a yellowish-white thin film for the phytosomes,  but a 
longer time of approximately 120 minutes to produce a yellow-brownish thin lipid 
film for the liposomes,. Both of the lipids used worked fine to provide effective thin 
films for the phytosomes and liposomes. The hydration of the thin films for the 
phytosomes required 10 to 20 minutes (i.e. less than that for liposomes) of hand 
shaking and vortexing to form the phytosomes suspension, while it took 30 to 45 
minutes to form liposomes suspension.  Overall, the thin film hydration method 
thus worked well to produce both phytosomes and liposomes of S. frutescens 
FDAE. However, the phytosomes needed less time to form and was produced in a 
higher percentage yield than the liposomes. 
4.4.2.  Particle shape, size, size distribution and stability of the liposomes and 
phytosomes  
 
High Resolution Scanning Electron Microscopic (HR-SEM), Photon Correlation 
Spectroscopy (PCS) and the Zetasizer were used to determine the shape, size, size 
distribution and stability of the liposomes and phytosomes. 
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4.4.2.1 Scanning Electron Microscopy (SEM). 
As reported by Mainardes et al (2005), the sonication method used to downsize 
nano-particles usually produces particles that differ in size range and shape.  The 
SEM images obtained for the present study are given in figure 4.3 and shows that 
the particles had a size of ≥ 200 nm. Morphologically the liposomes were mostly 
spherical, while the phytosomes were mainly rod-shaped. 
 
Figure 4.3 The Scanning Electron Microscopy images showing the shape 
and size of S. frutescens liposomes (A) and phytosomes (B). 
 
4.4.2.2  Photon Correlation Spectroscopic (PCS) Analysis 
The mean particle size and size distribution of the prepared liposomes and 
phytosomes were also determined by PCS. The primary goal in the present study 
was to obtain liposomes and phytosomes of sufficiently small (i.e. nano particle) 
size and the results obtained are shown in figure 4.4. Generally, nanoscale particles 
were obtained with the mean sizes of the Sutherlandia extract, quercetin and rutin 
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liposomes being 230.8 ± 38.4, 451.05 ± 69.79 and 359.6 ± 56.05 nm, respectively, 
and significantly (p < 0.01 for S. frutescens, p < 0.05 for quercetin) greater than the 
mean phytosomal sizes  of 675.23± 32.17, 811.4± 41.02 and 291.17 ± 45.07 nm, 
respectively. The difference in the rutin liposome versus phytosome sizes were not 
significant (p > 0.05). The High Resolution Scanning Electron Microscopic (HR-
SEM) and Photon Correlation Spectroscopy (PCS) results thus indicated similar 
sizes for the liposomes and phytosomes. 
 
Figure 4.4 Size of the liposomes and phytosomes containing S. frutescens, 
quercetin and rutin (n = 3 ± std). 
 
Generally, liposomes and phytosomes of the sizes obtained in the present study are 
considered to be promising vehicles for delivery of herbal medicine (Zhang et al. 
2013). Moreover, particles greater than 100 nm, as obtained in this study, are 
classified as large unilamellar vesicles (LUV) and this size of vesicles have been  
reported  to be more suitable and accepted for food applications (Akbarzadeh et al. 
2013).  The quercetin and rutin (its glycoside) liposomes were approximately 
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similar in size and had comparable sizes to that obtained by Goniotaki in his 
formulations of liposomes (Goniotaki et al. 2004).  
 Overall, the results indicated that, after sonication, liposomes and phytosomes of S. 
frutescens, quercetin (flavonoid aglycone) and rutin (flavonoid glycoside) of 
sufficiently small sizes were obtained and these could be acceptable formulations for 
further in vivo and in vitro studies.  
Photon Correlation Spectroscopic (PCS) analysis was also used to assess the 
particle size distribution, presented as the polydispersity index (PDI), and the results 
obtained are given in figure 4.5. The PDI of the Sutherlandia extract and quercetin 
liposomes were 0.366 ± 0.1 and 0.890 ± 0.12, respectively, and significantly (p < 
0.01) different than the 0.94± 0.1 and 0.105± 0.1 values, respectively, for the 
phytosomes. The PDI of the rutin liposomes (i.e. 0.458± 0.006) and phytosomes 
(i.e. 0.453± 0.021) was however not significantly different (p > 0.05).  
 
Figure 4.5 Polydispersity Index (PI) of the liposomes and phytosomes 
containing S. frutescens, quercetin and rutin (n =3± std). 
 
The polydispersity index (PDI) reflects the homogeneity of the sizes of particles in 
a formulation with values of 0 indicating monodisperse and 1 polydisperse 
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populations while a value of > 0.5 (more than 0.5) indicate broad distributions and 
< 0.5 homogenous distributions (Iqbal et al. 2012). The results obtained suggested 
that the liposomes of the Sutherlandia extract and rutin and phytosomes of the 
quercetin and rutin all had homogeneous size distributions (PDI < 0.5), while the 
quercetin liposomes and S. frutescens extract phytosomes showed broad size 
distributions (PDI > 0.5). The sonication method of size reduction was therefore 
clearly effective but worked better for the liposomes than the phytosomes of S. 
frutescens extract in this study.  
 
4.4.2.3  Zeta potential analysis of liposomes and phytosomes. 
Zeta potential (ZP) analysis was used to determine the stability of the phytosome 
and liposome formulations and the results that were obtained are given in figure 
4.6.  
All the ZP values were negative because the lipids used were neutral (ONG YUNG 
SHENG 2007). The values for the Sutherlandia extract, quercetin and rutin 
liposomes were -8.55 ± 0.26 , -16.6 ± 0.35 and   -5.15  ±  0.77 mv, respectively and 
significantly (p < 0.01 for S. frutescens, quercetin and rutin) different than the  -
0.457± 0.06, -2.63± 0.68  and -3.18± 0.16 mv respective ZP values for the 
phytosomes.  The zeta potential for the phytosomes prepared with 
phosphatidylcholine was around 0 mv, indicating a neutral surface charge. On the 
other hand the liposomes, prepared using lecithin, had greater negative zeta 
potential values suggesting better stability than that of the phytosomes.  
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Figure 4.6  Zeta potential of the liposomes and phytosomes containing S. 
frutescens, quercetin and rutin (n = 3 ± std). 
 
The zeta potential reflects the electric repulsion between particles and, in general, 
nanoparticles form a stable dispersion when the absolute value of zeta potential is 
above + 30 mv or below – 30 mv (Yan, et al. 2012). Although the absolute zeta 
potential values for the liposomes and phytosomes prepared in the present study 
were between  +  30 mv and  – 30 mv, the liposomes showed a relatively higher ZP 
value suggesting that it had  better physical and chemical stability than the 
phytosomes. 
 
Overall, the liposomes and phytosomes obtained were both of sufficiently small 
(i.e. nano particle) size. In addition, the liposomes had a narrower size distribution, 
and better stability than the phytosomes (i.e. broad size distribution), suggesting 
that they can better deliver precise amounts of API for better cell penetration.  
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4.4.3 HPLC assay method  
A reversed phase HPLC separation method combined with DAD detection was 
developed for the assay of S. frutescens flavonoids (e.g. glycosides and aglycones), 
quercetin and rutin in liposomes and phytosomes. With the developed method, the 
compounds of interest were separated and detected within 35 minutes using a C18 
column, gradient elution with acetonitrile and formic acid (ACN formic acid) and 
UV detection by DAD. Representative chromatograms from the assay are shown in 
figures 4.7, 4.8 and 4.9. They showed that the retention times for sutherlandin A, 
B, C and D were 12.3, 13.5, 16.03 and 16.88 minutes, respectively, and that for 
quercetin 24.6 minutes and for rutin 10.7 minutes.  
 
 
Figure 4.7 HPLC chromatogram of aqueous S. frutescens solution 
measured at λ = 370 nm. Concentration of S. frutescens solution 
was 6.66 mg/ml, the injection volume 20 µl and Suth A, B, C, and 
D equal to Sutherlandins A to D.  
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Figure 4.8 HPLC chromatogram of quercetin measured at λ = 370 nm. 
Concentration of solution was 2 mg/ml, and injection volume 20 
µl.   
 
Figure 4.9   HPLC chromatogram of rutin measured at λ = 370 nm.   
                 Concentration of solution was 2 mg/ml, and injection volume 20 µl. 
4.4.3.1  Validation of HPLC assay 
The following are the results of the validation of the HPLC assay for flavonoids in 
solution.  
 
4.4.3.1.1 Calibration curves and linearity 
The calibration curves representing the reference compounds are presented in 
Appendix 2 and the results of the curve analyses in Table 4.1. The six point curves 
for all the reference compounds showed strong linear correlations, i.e. r2 > 0.99, 
between concentration and peak area of the detector response (Table 4.1).  
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Table 4.1:  Summary of parameters for HPLC assay of flavonoid glycosides and 
aglycones.  
 
Flavonoid Regression 
equation 
Concentration 
range (μg/ml) 
r2 LOD 
(ug/ml) 
LOQ 
(ug/ml) 
Sutherlandin A y = 22.252x – 
9.5909 
4.0 to 180.0 0.9998 2 4 
Sutherlandin B y = 14.543x + 
13.149 
4.0 to 200.0 0.9996 4 4 
Sutherlandin C y = 17.890x + 
11.763 
4.0 to 200.0 0.9990 4 15 
Sutherlandin D y = 17.45x - 1.5755 4.0 to 180.0 0.9996 2 4 
Quercetin  y = 108.51x + 
104.95 
4.0 to 120.0 0.9967 < 2 9 
Rutin  y = 27.88x + 35.835 4.0 to 120.0 0.9988 < 2 15 
LOD = Limit of detection and LOQ = Limit of quantitation                
 
4.4.3.1.2 Limit of detection (LOD) and limit of quantitation (LOQ) 
The values for the LOD and LOQ are presented in Table 4.1. The LOQ was lowest 
for sutherlandins A, B and D, and highest for sutherlandin C and rutin. The results 
obtained suggested that the proposed method was sensitive enough for the assay of 
flavonoid glycosides (i.e. sutherlandins A to D and rutin), and aglycones (i.e. 
quercetin) in the manufactured liposomes and phytosomes. 
4.4.3.1.3 Precision and accuracy  
Precision and accuracy data for the reference standards are shown in Tables 4.2. 
The % RSD for most of the reference standards were less than 3%, suggesting that 
the proposed method was precise enough for the assay of flavonoid glycosides in 
 
 
 
 
64 
 
Sutherlandia. Exceptions were sutherlandin B and sutherlandin C for which % RSD 
at lower concentrations were 5.75 and 3.80, respectively. Precision data less than 
5% RSD may be acceptable (Costa et al, 2011), more so for herbal materials where 
variation in actives may be quite considerable (Ghosh et al. 2012; Gao and Hu, 
2010). The interday and intraday assay precision was also consistent, with % RSD 
less than 1% for all the reference standards.  
Overall, the HPLC method developed was thus simple but had relatively good 
separation, accuracy and precision and sufficiently wide linear concentration ranges 
to determine the levels of the flavonoid aglycone (e.g. quercetin), and glycosides (i.e. 
sutherlandins A, B, C and D, and rutin) in, or released from, the S. frutescens, 
quercetin and rutin containing liposomes and phytosomes. 
 
 
Table 4.2:  Precision and accuracy data for quantification of the reference 
standards at 370 nm. 
 
 
 
 
 
 
 Reference compound % RSD 
Lower conc. (ug/mL): 15 ug/mL Sutherlandin A 2.01 
Higher conc. (ug/mL): 33 ug/mL Sutherlandin A 2.54 
   
Lower conc. (ug/mL): 15 ug/mL Sutherlandin B 5.75 
Higher conc. (ug/mL): 35 ug/mL Sutherlandin B 2.83 
a   
Lower conc. (ug/mL): 15 ug/mL Sutherlandin C 3.80 
Higher conc. (ug/mL): 35 ug/mL Sutherlandin C 2.14 
   
Lower conc. (ug/mL): 15 ug/mL Sutherlandin D 2.36 
Higher conc. (ug/mL): 33 ug/mL Sutherlandin D 2.29 
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4.4.4
 Flavonoid encapsulation efficiency of liposomes and phytosomes. 
The levels of flavonoids encapsulated in liposomes and phytosomes were 
determined by HPLC assay and percentage EE calculated.  And the results obtained 
are summarized in appendix 3 and figures 4.10 and 4.11.  
The % EE value of the flavonoids in the Sutherlandia extract containing 
phytosomes were 47.62± 3.76, 48.83± 3.75, 43.46± 3.44, and 46.75± 5.01 % for 
sutherlandins A, B, C and D, respectively, and this was significantly (p < 0.001 for 
sutherlandins A and B and p < 0.01 for sutherlandins C and D) greater than the 
liposomal EE % of 26.93± 3.56, 28.51± 2.3, 26.62± 3.18, and 32.53± 8.51 %, 
respectively. The greater sutherlandin flavonoid EE % of the phytosomes was 
probably as a result of complex formation between the lipid and drug as reported 
by Hou (Hou et al. 2012). On the other hand, the flavonoid EE % of the liposomes 
was rather low, most likely due the low affinity for, and solubility of the 
Sutherlandia extract flavonoids in, the lipid constituting the liposomal 
   
Lower conc. (ug/mL): 8 ug/mL Quercetin  2.84 
Higher conc. (ug/mL): 35 ug/mL Quercetin 1.28 
   
Lower conc. (ug/mL): 9 ug/mL Rutin 2.39 
Higher conc. (ug/mL): 35 ug/mL Rutin 2.21 
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Figure 4.10  Flavonoids glycoside encapsulation efficiency of liposomes and 
phytosomes containing S. frutescens (n = 3 ± std).   
 
membrane which then decreased the chances of the extract (and thus sutherlandins) 
being entrapped in the aqueous compartment. The lower amounts of extract 
entrapped then resulted in the lower individual flavonoid EE % (Fahr, Liu 2007). 
In the phytosomes the extract constituents could however bind to the lipid bilayer 
which prevented the drug from escaping and produced the higher flavonoid EE % 
observed in the phytosomes (Maya et al. 2013). Overall, these results confirmed the 
first hypothesis viz. that the entrapment efficacy of the phytosomes will be higher 
than that of the liposomes.  
 
For the quercetin (i.e. the flavonoid aglycone) the % EE in the phytosome was 85.94 
± 1.87 % and significantly (p < 0.05) greater than the 48.75 ± 11.8 % for liposome. 
This finding may be due to complex formation between quercetin and the 
phosphatidylcholine or because quercetin, due to the it’s planar configuration that can 
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easily locate into the organized structure of the phospholipids within the phytosomes 
membranes, had a higher affinity for the phytosomes (Rasaie et al. 2014).  
The EE % for rutin in the liposomes and phytosomes, i.e. 69.15 ± 0.33 % versus 
66.39 ± 0.05 %, was however not statically different (p > 0.05).  And this was most 
likely due to the ability of this glycoside to bind in both the core and lipid bilayer 
of the nanoparticles. Rutin is a water soluble compound which, in liposomes, has a 
chance of being entrapped in the aqueous compartment, while in the phytosome, 
uniform binding of rutin and phosphatidylcholine is possible (Das, Kalita 2014).  
 
 
Figure 4.11 Encapsulation efficiency (%) of rutin and querctin containing 
liposomes   versus phytosomes (n = 3 ± std). 
 
Overall, the EE % for rutin (the glycoside) in the liposomes and phytosomes were 
high and not statically different (i.e. 69 versus 66 %), for quercetin (the aglycone) 
significantly better in phytosomes than liposomes (i.e. 85 versus 48 %) and for the 
sutherlandins (i.e. glycosides) contained in the FDAE of S frutescens, significantly 
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higher in phytosomes than liposomes (i.e. 50 versus 26 %). All of this can possibly 
be attributed to the fact that the FDAE of Sutherlandia also contained a matrix of 
other constituents, such as sugars i.e. polysaccharides, etc., which were also (or 
even more) water soluble than the sutherlandins and could compete in the 
entrapment process resulting in the low EE % of sutherlandins in the liposomes, 
while complex formation between the lipid and sutherlandins in the phytosomes 
could be a reason for the higher encapsulation efficacy in this nanoparticle. Overall, 
these results confirm the first hypothesis viz. that the entrapment efficacy of the 
phytosomes will be higher than that of the liposomes.   
 
4. 5  Conclusion   
In this present study, a successful method was developed to obtain preparations of the 
S. frutescens liposomes and phytosomes. The sonication method was effective to 
obtain small particle size (i.e. nano range) for both the liposomes and phytosomes. 
However, the liposomes had a smaller size; narrower size distribution; higher zeta 
potential and better stability than the phytosomes, suggesting that they can better 
deliver precise amounts of API for better cell penetration. In addition, the 
phytosomes, however, had significantly higher encapsulation than the liposomes (±50 
% versus ±26 %) suggesting that, most probably due to the complex formed between 
the API and the lipid, but suggesting that phytosomes can serve as the more promising 
vehicles to carry different active constituents of the herbal extract. Moreover, this 
latter finding confirmed the first hypothesis, viz. that the entrapment efficacy of the 
phytosomes would be higher than that of the liposomes.   
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In general, the results indicated that the prepared liposome and phytosome 
formulations could indeed be promising vehicles for delivery of hydrophobic and 
hydrophilic compounds found in herbal extracts,  might be able to facility their 
rapid absorption and this needs to be investigated further in in vivo and in vitro 
studies. 
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CHAPTER FIVE 
Flavonoid release profile of S. frutescens containing liposomes and 
phytosomes 
 
5.1  Introduction 
One of the main objectives of this study was to investigate and compare the in vitro 
release profile of S. frutescens flavonoids (as active phytopharmaceutical ingredient 
or API) from with liposomes versus that from phytosomes.  Firstly, to quantitate 
the amount of flavonoids released, an HPLC assay was used. Secondly, pH 1.2 and 
6.8 buffers solutions were used to simulate the release that would occur under 
gastrointestinal conditions and samples were taken at specific time intervals to 
provide a drug release over time profile for both the liposomes and phytosomes. 
Finally, the percentage API released after 120 minutes was determined and used as 
a parameter to compare profiles of flavonoid released from the liposomes and 
phytosomes.  In this chapter the chemicals, materials and equipment, as well as the 
methods used are described, and the results obtained presented and discussed. 
 
5.2  Chemicals, Materials, and Equipment. 
All the chemicals, materials and equipment used in this part of the study are given in 
section 4.2. In addition, pH 1.2 and 6.8 buffer solutions were used and these were 
prepared using methods found in the BP (2014).  Briefly, for the pH 1.2 buffer 
solution, 9.7 ml of concentrated hydrochloric acid (concentration, 32%) was diluted 
with distilled water up to a volume of 1000 ml.  For the pH 6.8 buffer solution, 21.72 
g of anhydrous dibasic sodium phosphate was dissolved in 1 L distilled water and the 
pH adjusted with a few drops of 2 M hydrochloric acid solution. Finally, the 
liposomes and phytosomes evaluated were those prepared as was explained in section 
4.3.1 and 4.3.2. 
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5.3 Determination of in vitro flavonoid release. 
The release profile of S. frutescens flavonoids from the liposomes and phytosomes 
were examined using the method of Kadare et al. (Kadare et al. 2014) and two 
different buffer solutions to mimic conditions obtained in different sections of the 
gastrointestinal tract (GIT). The medium at pH 1.2 represented gastric conditions 
while the medium at pH 6.8 represented prevalent pH conditions in the small 
intestine.  
For the flavonoid release studies, 2 ml of either buffer solution were added to six 
numbered (i.e. 1 to 6) 10 ml Eppendorff tubes containing the pellets of liposomes 
or phytosomes (Note: the pellets were prepared as described in section 4.3.3), and 
time recorded as time equal to zero. Three replicates (n=3) of the 6 tubes were used. 
The eppendroff tubes were placed in a water bath maintained at 37± 0.5 OC and at 
specific time intervals (i.e. 5, 15, 30, 60, 90 and 120 minutes, respectively), the 
tubes representing the time interval (i.e. tube # 1 at 5 minutes, tube number two at 
15 minutes, etc.) were removed, 1 ml sample drawn from each one and the 
withdrawn samples centrifuged at 20,000 rpm for 30 minutes. The supernatant was 
removed with a syringe, filtered through a 0.45 µm syringe filter, transferred to 
HPLC vials and analysed using the validated HPLC method (Mbamalu et al., 2015) 
described in sections 4.3.7 and 4.4.3.  
 
From the HPLC chromatograms the peak areas for the individual sutherlandins (A 
to D) were obtained and the percentage release calculated using the following 
formula: 
 
Drug release (%) =       X 100 
Peak area of flavonoid released at specified time point  
Peak area of flavonoid loaded into pellet 
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The peak area of flavonoid released at specified time point was determined as described 
above.  To obtain the total peak area of flavonoid loaded into pellet, 200 µl of Triton 
X100 was added to samples of pellet contained in 2 ml pH 1.2 or 6.8 buffer and the 
mixture vortexed for 10 minutes to break up and dissolve the phospholipid. Then, 1 ml 
sample was withdrawn from each tube and the withdrawn samples centrifuged at 20,000 
rpm for 30 minutes, the supernatant removed with a syringe, filtered through a 0.45 µm 
syringe filter and the filtered solution transferred to HPLC vials from which  20 µl was 
injected unto the HPLC column. The areas of the relevant sutherlandin peaks were then 
obtained from the chromatogram, taken as the total amount of flavonoid loaded into 
pellet and used to determine the percentage drug release.  
 
The percentage drug released versus time data was plotted, using GraphPad Prism, 
to obtain the drug release versus time profile for each of the sutherlandins from the 
liposomes and phytosomes. Several parameters were used to compare the release 
profiles. First, the average amount released at 120 minutes (i.e. AR120) and average 
time required for 50 % release (i.e. TAR50) were determined and compared using the 
student t-test.  Next, each combination of the flavonoid release profiles was 
compared using the similarity factor calculated using the following equation: 
 
 
Where Rt and Tt are the average percent released at each time point for the reference 
(liposome) and test (phytosome) products, respectively, and n is the number of 
observations. An f2-value between 50 and 100 was taken to indicate similarity of 
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two release profiles while values below 50 indicate dissimilarity (Shah et al. 1999) 
and this criterion was used to compare the product profiles. All assessments were 
carried out in triplicate.   
 
5.4 Results and discussion 
5.4.1  Sutherlandin release in pH 1.2 buffer solution 
The total amounts (AR120) and rates (TAR50) of sutherlandins (A to D) released from 
the liposomes and phytosomes found are presented in table 5.1, figure 5.1 and 
Appendix 4 (i.e. the data from which the graphs were plotted).  
 
Figure 5.1:  Release profiles of sutherlandins A, B, C and D from S. 
frutescens liposomes and phytosomes at pH 1.2.   
Neither the liposomes nor the phytosomes released all (i.e. 100 %) of the individual 
sutherlandins after 120 mins in pH 1.2 buffer (i.e. AR120 < 100 %) and the amounts 
released at all time points were significantly (i.e.  p = 0.0033 for sutherlandins A, p 
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= 0.0021 for sutherlandin B, p = 0.001 for sutherlandin C, and p = 0.0145 for 
sutherlandin D) higher from the liposomes than that from the phytosomes.  The 
amounts of  sutherlandins A, B, C, and D released from the liposomes at 120 mints, 
as a percentage of the total amount in the encapsulated S. frutescens material, were 
62.96, 58.09, 75.74 and 45.74%, respectively, and 51.66, 41.33, 50.74 and 38.75 %, 
respectively for the phytosomes.  Despite the higher flavonoid encapsulation 
efficiency of the phytosomes, established in chapter 4, the liposomes still released 
higher amounts of each flavonoid, after 120 mins in pH 1.2 buffer, than the 
phytosomes.  
The sutherlandins were released at different rates from the liposomes with the time 
for 50% release ( i.e.TAR50) being 5 minutes for sutherlandin B and C,  30 minutes for 
sutherlandin A and > 120 minutes for sutherlandin D. These rates were however faster 
than that for the phytosomes for which the TAR50 for sutherlandins A and C 
phytosomes were 60 minutes and > 120 minutes for sutherlandins B and D. 
 
Table 5.1: The percentage release (AR120) and rate of release (TAR50) of the 
sutherlandins from Sutherlandia containing liposomes and 
phytosomes at pH 1.2 
Sutherlandins 
Liposomes Phytosomes 
AR120 (%) TAR50  (Minutes) AR120 (%) TAR50   (Minutes) 
Sutherlandin A 62.96 30 51.66 60 
Sutherlandin B 58.09 5 41.33 > 120 
Sutherlandin C 75.74 5 50.74 90 
Sutherlandin D 45.74 
None of time 
intervals 
38.75 > 120 
 
The individual sutherlandin release profiles from the liposomes and phytosomes were 
also compared and the similarity factors (f2) for sutherlandins A, B, C and D release 
 
 
 
 
75 
 
from the liposomes versus phytosomes were 40, 33, 27 and 50, respectively, clearly  
indicating the dissimilarities of the release profiles of each sutherlandin from the 
liposomes versus the phytosomes. The f2 value for sutherlandin D was 50, indicating 
similarity; however, this value is at the margin of similarity. 
The faster release of the APIs from the liposomes compared to the phytosomes is in 
agreement with previous studies which reported that API release profiles from 
liposomes characteristically show an initial faster API release followed by slower 
rates which may be due to the large specific surface area and higher API content 
located on the liposomal surface. It may also be caused by API adsorption on the nano 
particle surface of the liposome (Lockman et al. 2002).  
Compared to the liposomes, API release from the phytosomes was however more 
constant and sustained right from the initial stages of API release. This may be due 
to an increase in diffusional distance and the hindering effects of the surrounding 
solid lipid shell found in the phytosome (Sadiq, et al 2014). It may also be due to 
complex formation between the API and phospholipid (i.e. phosphatidylcholine) in 
the phytosome preparation (Patel et al. 2009). 
It was interesting to note that the percentages of sutherlandins A, B, C, and D 
released from the phytosomes in the pH 1.2 buffer was increased at 24 h, while their 
percentages released from the liposomes stayed the same as the AR120 values. This 
suggests that the phytosomes exhibited sustained flavonoid glycoside release in 
acidic medium.  
 
For quercetin, i.e. the flavonoid aglycone, no release was detected from the 
phytosomes containing quercetin at 120 minutes in pH 1.2 buffer, but 49.5 % 
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release in the 24 hour samples. In addition, no quercetin release was detected from 
the liposomes at 24 hours, suggesting that the phytosomes (but not the liposomes) 
has the ability to serve as carriers for both flavonoid glycosides and aglycones.  
 
To determine whether one or all of the sutherlandins would be required if one 
wishes to compare the API release character or quality of Sutherlandia containing 
liposomes or phytosomes at pH 1.2, the release profiles and data presented in figure 
5.2 and table 5.1 were considered. 
 
 
 
Figure 5.2 Release profiles of individual sutherlandins A, B, C and D from 
S. frutescens liposomes and phytosomes at pH 1.2.  
 
 
 
Table 5.2: Comparison of release profile of individual sutherlandins A, B, C, 
and D from liposomes at pH 1.2 
Sutherlandin comparison Similarity factor  (f2) Inference 
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Suth A vs Suth B 61 Release profile similar 
Suth A vs Suth C 46 Release profile dissimilar 
Suth A vs Suth D 39 Release profile dissimilar 
Suth B vs Suth C 41 Release profile dissimilar 
Suth B vs Suth D 43 Release profile dissimilar 
Suth C vs Suth D 27 Release profile dissimilar 
   
For sutherlandin release from the liposomes at pH 1.2, the f2 values were all below 
50 with the exception of sutherlandin A versus sutherlandin B (f2 = 61). This implies 
that the release profiles of sutherlandins A and B were similar but dissimilar for all 
the other comparisons (i.e. A versus C, A versus D, B versus C, B versus D, and C 
versus D). This could be because sutherlandins A and B are glycosides of the same 
aglycone, quercetin. However, if this is so, then we expected the release profiles of 
sutherlandins C and D to be similar as well because they are glycosides of the same 
aglycone, viz. kaempferol. This was not the case though. It may be that glycosides 
of quercetin are more similar than glycosides of kaempferol, and the difference in 
the sugar moieties of sutherlandins C and D could also contribute to the 
dissimilarity of their release profiles.  No evidence to substantiate or refute this 
proposition could however be found in literature.  
 
For the phytosomes, the results of the release profile comparisons of the different 
sutherlandins at pH 1.2 are presented in figure 5.2 and table 5.3. 
 
 
 
 
 
78 
 
Table 5.3:  Comparison of release profile of individual sutherlandins A, B, C, 
and D from   phytosomes at pH 1.2 
Sutherlandin comparison Similarity factor (f2) Inference 
Suth A vs Suth B 54 Release profile similar 
Suth A vs Suth C 87 Release profile similar 
Suth A vs Suth D 50 Release profile similar 
Suth B vs Suth C 54 Release profile similar 
Suth B vs Suth D 50 Release profile similar 
Suth C vs Suth D 74 Release profile similar 
 
 In this case the f2 values were all above 50, implying similarity of the release 
profiles of all the sutherlandins from the phytosome preparations. This is different 
from what was obtained with the liposomes where most of the sutherlandins showed 
dissimilarity in drug release profiles. It could well be that  the phytosome 
preparation masks the characteristics of individual sutherlandins, so that their 
release depend on the enclosing material while in the liposome preparation the 
individual characteristics of the sutherlandins are preserved leading to differences 
in sutherlandin release from the liposomes but not from the phytosomes. These 
observed differences could also be due to the bonding characteristics of the 
sutherlandins being different within the phytosomes but not within the liposomes.  
No confirmation of these possibilities was however found in the literature.  
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Collectively, the above results indicated that there were significant differences in 
the release profiles of the S. frutescens flavonoid glycosides from liposomes versus 
phytosomes at pH 1.2 i.e. in gastric conditions, a characteristic shown by all the 
individual sutherlandins. The differences observed might reflect differences in the 
sutherlandin encapsulation efficacy or surface area in the liposomes and 
phytosomes.  In addition, for comparison of API release from different phytosome 
preparations of Sutherlandia, as a product quality control specification, any of the 
4 sutherlandins can be considered, but not for liposome preparations, in which case 
all 4 marker compounds should be used.  
 
 
5.4.2 Sutherlandin release in pH 6.8 buffer solution 
The total amounts (AR120) and rates (TAR50) of sutherlandins (A to D) released from 
the liposomes and phytosomes are presented in table 5.4, figure 5.3 and Appendix 4 
(i.e. the data from which the graphs were plotted). 
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Figure 5.3: Release profiles of sutherlandins A, B, C and D from S. 
frutescens liposomes versus phytosomes at pH 6.8. 
 
Neither the liposomes nor the phytosomes released all (i.e. 100 %) of the individual 
sutherlandins after 120 mins in pH 6.8 buffer (i.e. AR120 < 100 %) and the amounts 
released at all time points were significantly (p = 0.001 for sutherlandins A and p = 
0.0008 for sutherlandin B, C and D), higher for the liposomes than that from the 
phytosomes. The amounts of  sutherlandins A, B, C, and D released from the 
liposomes at 120 mins, as a percentage of the total amount of the encapsulated S. 
frutescens material, were 77.47, 75.78, 86.76 and 88.86%, respectively, and 30.55, 
30.76, 32.65 and 44.93%, respectively for the phytosomes.  Despite the higher 
flavonoid encapsulation efficiency of the phytosomes, established in chapter 4, the 
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liposomes still released higher amounts of each flavonoid, after 120 minutes in pH 
1.2 buffer, than the phytosomes.  
The sutherlandins were released at different rates from the liposomes with the time 
for 50% release ( i.e.TAR50) being 5 minutes for sutherlandin D and  30 minutes for 
sutherlandins A, B and C. These rates were however faster than that for the 
phytosomes for which the TAR50 for all sutherlandins of the phytosomes > 120 
minutes.  
 
Table 5.4: The percentage release (AR120) and rate of release TAR50 form the 
liposomes and phytosomes at pH 6.8 
 
Sutherlandins 
Liposomes Phytosomes 
AR120 (%) TAR50  (Minutes) AR120 (%) TAR50   (Minutes) 
Sutherlandin A 77.47 30 30.55  > 120 
Sutherlandin B 75.78 30 30.76  > 120 
Sutherlandin C 86.76 30 32.65  > 120 
Sutherlandin D 88.86 5 44.93  > 120 
 
 
 
The individual sutherlandin release profiles from the liposomes and phytosomes 
were also compared and the similarity factors (f2) for sutherlandins A, B, C and D 
release from the liposomes versus phytosomes were 22, 19, 17 and 21, respectively, 
clearly  indicating the dissimilarities of the release profiles of each sutherlandin 
from the liposomes versus the phytosomes.  
. 
Generally, the liposomes showed faster flavonoid release than the phytosomes. 
Release of the sutherlandins was also faster at pH 6.8 than at pH 1.2, probably due 
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to the enhanced solubility of liposomes at higher pH values. The phytosomes, on 
the other hand, exhibited slower sutherlandin (API) release at pH 6.8. Release of 
API from solid dosage forms is a complex operation influenced by a number of 
factors such as differences in surface area, stability, particle size and size 
distribution (Chiou, et al 1971). The significant enhancement of API release from 
the liposomes compared to the phytosomes could be due to the greater physical 
stability of the liposomal preparation (confirmed by zeta potential values for 
liposomes of - 8.55) than that of phytosomes (zeta potential value of - 0.457) (Lim, 
Kim 2002).The smaller size of the liposome vesicles could be another factor 
contributing to the increased API release of S. frutescens flavonoids. Indeed, it has 
been demonstrated in a previous study that the minute size of the liposomes 
provided a bigger surface area compared to that of phytosomes (Ait-Oudhia, et al. 
2014), and that this hastened API release from the liposomes. 
 
To determine whether one or all of the sutherlandins would be required if one 
wishes to compare the API release character or product quality of Sutherlandia 
containing liposomes or phytosomes at pH 6.8, the release profiles and data 
presented in figure 5.4 and table 5.3 were considered. 
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Figure 5.4 Release profiles of individual sutherlandins A, B, C and D from 
S. frutescens liposomes and phytosomes at pH 1.2. 
   
 
Table 5.5: Comparison of release profile of individual sutherlandins A, B, C, 
and D from   liposomes at pH 6.8 
 
Sutherlandin comparison Similarity factor (f2) Inference 
Suth A vs Suth B 75 Release profile similar 
Suth A vs Suth C 48 Release profile dissimilar 
Suth A vs Suth D 45 Release profile dissimilar 
Suth B vs Suth C 51 Release profile similar 
Suth B vs Suth D 48 Release profile dissimilar 
Suth C vs Suth D 56 Release profile similar 
 
Generally the f2 – values for sutherlandin release from the liposomes at pH 6.8 were 
higher than those obtained at pH 1.2.  At the higher pH the release profiles of 
sutherlandins A versus B, B versus C and C versus D were similar, but dissimilar 
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for all the other comparisons (i.e. A versus C, A versus D, and B versus D). This 
could have been because sutherlandins A and B are glycosides of the same 
aglycone, quercetin, while sutherlandins C and D are glycosides of the aglycone 
kaempferol, or it might be also due to increased stability of the liposomes at the 
higher pH.   
 
The results for the release profile comparisons of the different sutherlandins from 
the phytosomes at pH 6.8 are presented in figure 5.4 and table 5.6. 
 
Table 5.6: Comparison of release profile of individual sutherlandins A, B, C, 
and D from   phytosomes at pH 6.8 
Sutherlandin comparison Similarity factor (f2) Inference 
Suth A vs Suth B 72 Release profile similar 
Suth A vs Suth C 88 Release profile similar 
Suth A vs Suth D 50 Release profile similar 
Suth B vs Suth C 88 Release profile similar 
Suth B vs Suth D 50 Release profile similar 
Suth C vs Suth D 52 Release profile similar 
 
The f2 values were all above 50, implying similarity of the release profiles of all the 
sutherlandins from the phytosome preparations. It could well be that in the 
phytosome preparation the structural characteristics of individual sutherlandins 
were masked, so that their release depended on the enclosing material while in the 
liposome preparation the individual characteristics of the sutherlandins were 
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preserved leading to differences in sutherlandin release from the liposomes but not 
from the phytosomes. The observed differences could also be due to the bonding 
characteristics of the sutherlandins which might also be different within the 
phytosomes but not within the liposomes.  No confirmation for either of these 
possibilities was however found in the literature. 
  
Collectively, the above results indicated that there were significant differences in 
the release profiles of the S. frutescens flavonoid glycosides from liposomes versus 
phytosomes at pH 6.8 i.e. in intestinal fluid, a characteristic shown by all the 
individual sutherlandins. The differences observed might reflect differences the 
encapsulation efficacy or surface area of the API in the liposomes and phytosomes.  
In addition, for comparison of API release from different phytosome preparations 
of Sutherlandia, (e.g, for product quality control purposes) any of the 4 
sutherlandins can be considered, but not for liposome preparations, in which case 
similarity was only found for Sutherlandia A versus B, sutherlandin B versus C and 
sutherlandin C versus D, and preferably all 4 should be monitored. 
 
5.4.3 Effect of pH on flavonoid release from liposomes and phytosomes. 
Finally, the effect that pH had on flavonoid release was also assessed and the 
results of  comparison of sutherlandins A, B, C and D release from the 
Sutherlandia liposomes and phytosomes at pH 1.2 and 6.8 are presented in figures 
5.5 and 5.6.  
 
 
 
 
86 
 
 
Figure 5.5:  Effect of pH on release profiles of sutherlandins A, B, C and D 
from S. frutescens liposomes  
 
The release profile for sutherlandins A and C from Sutherlandia liposomes at pH 
1.2 versus 6.8 were similar with f2 values of 52, and 54 respectively and pH 
therefore did not significantly affect the release profile of these sutherlandins. 
However, the release of sutherlandin B and D from Sutherlandia liposomes at pH 
1.2 and 6.8 was not similar with f2 values of 42 and 24, respectively. In addition, 
for sutherlandin B the release at the 2 pH’s was similar up to 60 minutes (with f2 
value 52), but after 60 minutes, it became dissimilar. Finally, the release of 
sutherlandin D was clearly dissimilar at the 2 pH’s and this was most likely due to 
instability of this API in the media.  
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For phytosomes, the release profile for sutherlandins A, B and C (with the exception 
of sutherlandin D, f2 = 65) from Sutherlandia phytosomes at pH 1.2 versus 6.8 were 
dissimilar with f2 values of 22, 44 and 39, respectively. Clearly pH affected the 
release profile of these 3 flavonoid glycosides from Sutherlandia phytosomes 
Overall, sutherlandin release from the phytosomes was more rapid  at pH 1.2 than 
pH 6.8, i.e. release rate was greater increased at the lower simulated gastric pH, 
while for liposomes  change of pH (from 1.2 to 6.8 ) did not significantly change 
the sutherlandin release profiles. 
 
Figure 5.6: Effect of pH on release profiles of sutherlandins A, B, C and D 
from S. frutescens phytosomes  
Overall, the release of sutherlandins A, B, C and D, i.e. potential active compounds 
of S. frutescens, was significantly higher and faster, from the liposomes compared 
to the phytosomes,  at both stomach (1.2) intestinal (6.8) pH, confirming the second 
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hypothesis tested in this study, viz. that sutherlandin release would be faster from 
the liposomes than from the phytosomes. In addition, for product quality control 
purposes, any of the 4 sutherlandins can be considered for comparison of API 
release from different phytosome preparations of Sutherlandia at both pH 1.2 and 
6.8, but not for liposome preparations. 
 
5.5  Conclusion 
The objective of this section of the study was to compare the in vitro release profiles 
of flavonoids from S. frutescens liposomes versus phytosomes. The release profiles 
of sutherlandins A, B, C and D showed significant differences with higher and faster 
release rates from the liposomes compared to the phytosomes at both pH 1.2 and 6.8. 
This may be due to the smaller particle size and narrower particle size range (as 
confirmed by the polydispersity index) of the liposomes compared to the phytosomes, 
attributes that facilitated the release of the API upon penetration of the buffer medium 
through the preparation matrix. Such penetration then resulted in rapid API diffusion. 
The phytosomes, with a larger size and broad particle size distribution, however 
released the API more slowly resulting in more delayed release. Finally, for product 
quality assessment any of the 4 sutherlandins can be considered for comparison of 
API release from different phytosome preparations of Sutherlandia at both pH 1.2 
and 6.8, but not for liposome preparations. In the latter all 4 sutherlandins might have 
to be used to obtain the best assessment.  
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CHAPTER SIX 
Conclusions and Recommendations 
 
The primary aim of this study was to prepare and compare liposomes and 
phytosomes of S. frutescens freeze dried aqueous extract (FDAE) for solid oral 
dosage form application. The specific objectives were to prepare and physically 
characterise liposomes and phytosomes of the S. frutescens FDAE and to determine 
the drug release profiles of flavonoids from these liposomes and phytosomes. 
  
From the results obtained in this study, the following major conclusions could be 
drawn: 
 
1. Both phytosomes and liposomes of S. frutescens FDAE can be efficiently 
prepared using the thin film hydration method. In addition, sonication was an 
effective method for size reduction of both types of particles, but, in this study, 
worked better for the liposomes than for the phytosomes of S. frutescens 
FDAE. 
2. The optimized liposomes and phytosomes had an appropriate vesicle size 
and carried a sufficient amount of drug. However, the prepared liposomes 
had smaller particle size and size distribution as well as a relatively higher 
zeta potential value than the phytosomes, suggesting that the liposomes had 
better physical and chemical stability profiles. 
3. Phytosomes can encapsulate significantly higher amounts of S. frutescens 
FDAE than do liposomes confirming the first hypothesis, viz. that the 
entrapment efficacy of the phytosomes will be higher than that of the 
liposomes, tested in this study, and also further strongly indicate that the 
phytosomes are promising vehicles for delivery of different active 
constituents of the herbal extract.  
 
 
 
 
90 
 
4. Finally, the release of sutherlandins A, B, C and D, potential active 
compounds of S. frutescens, was significantly faster, from the liposomes 
compared to the phytosomes,  at both stomach (1.2) and intestinal (6.8) pH, 
confirming the second hypothesis tested in this study, viz. that sutherlandins 
release would be faster from the liposomes than from the phytosomes.   
 
Collectively, the results obtained strongly suggest that phytosomes could be a very 
viable particle form for the delivery of flavonoids, and possibly other actives, (i.e. 
active phytopharmaceutical material) from an aqueous extract of S. frutescens.  
 
Overall, this study provides valuable preliminary information on the preparation 
and evaluation of liposomes and phytosomes of S. frutescens aqueous extract. 
Particularly the phytosomes may be the administration and delivery form to use for 
systemic delivery of S. frutescens and may most likely also be a useful delivery 
form for dried aqueous extracts of other South African indigenous medicinal plants. 
More detailed studies on the physical and pharmaceutical properties (e.g. flavonoid 
or other active compound dissolution profile; stability, etc.) of such products are 
however needed to confirm this potential usefulness. In addition, in vitro and in vivo 
pharmacokinetic studies of S. frutescens phytosomal and liposomal products will 
also be needed.  In the immediate future, we however aim to first investigate the 
optimization of the stability and lamellarity of the phytosomal preparations and the 
effect which cholesterol, as a formulation (and drug release) stabilizer, may have.   
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Appendix 1: Certificate of analysis for FDAE S. frutescens. 
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Appendix 2: Flavonoid calibration curves and regression equations. 
 
Figure A 2.1:  Calibration curves of sutherlandins (A to D) at 
wavelengths 370 nm. 
 
Figure A 2.2: Calibration curves of flavonoid glycoside (rutin) 
and aglycone (quercetin) at wavelengths 370 nm. 
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Appendix 3: HPLC peak areas of individual sutherlandins (A to D) 
released from liposomes and phytosomes and used to 
calculate entrapment efficacies. The peaks were 
obtained using method described in section 4.3.8 and 
detected at 370 nm 
 
 
Table A3.1: Peak area of individual sutherlandins released from liposomes 
 
Sutherlandin A Sutherlandin B 
Peak area of starting 
solution (mAUFs)   
Peak area of supernatant 
(mAUFs)   
Peak area of starting 
solution (mAUFs)    
Peak area of supernatant 
(mAUFs)   
723.2 441 1116 814.2 
721.8 540 1112.8 816.1 
851.2 584 1246 861.5 
Sutherlandin C Sutherlandin D 
Peak area of starting 
solution (mAUFs)    
Peak area of supernatant 
(mAUFs)   
Peak area of starting 
solution (mAUFs)    
Peak area of supernatant 
(mAUFs)   
1569.5 918.7 1168.7 995 
1568.6 1188.6 1108.5 775.8 
1715 1097.2 1105.9 640.5 
 
 
Table A3.2: Peak area of individual sutherlandins released from phytosomes 
Sutherlandin A Sutherlandin B 
Peak area of starting 
solution (mAUFs)     
Peak area of supernatant 
(mAUFs)   
Peak area of starting 
solution (mAUFs)    
Peak area of supernatant 
(mAUFs)    
851.2 478.8 1246 697.3 
851.2 423 1246 619.6 
851.2 422 1246 615 
Sutherlandin C Sutherlandin D 
Peak area of starting 
solution (mAUFs)     
Peak area of supernatant 
(mAUFs)   
Peak area of starting 
solution (mAUFs)    
Peak area of supernatant 
(mAUFs)   
1715.9 1043.1 1168.7 691.5 
1715.9 941.4 1168.7 590.8 
1715.9 941 1168.7 588.9 
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Appendix 4:   Sutherlandin release versus time profiles for FDAE 
Sutherlandia phytosomes and liposomes 
 
Table 4.1:  Release versus time profile for sutherlandin A from 
phytosomes of FDAE Sutherlandia at pH 1.2 and 6.8 
 
 
Time ( minutes) 
Percentage sutherlandin 
A released at pH 1.2 (%) 
 
Percentage sutherlandin 
A released at pH 6.8 
 
AVE ± SD %CV AVE ± SD %CV 
0 0 ± 0 0 0 ± 0 0 
5 46.560 ± 0.551 1.183 27.400 ± 1.058 3.862 
15 66.430 ± 0.321 0.484 32.667 ± 0.115 0.353 
30 80.300 ± 0.500 0.623 40.967 ± 0.862 2.105 
60 112.460 ± 0.153 0.136 57.400 ± 9.440 16.446 
90 114.000 ± 0.436 0.382 66.033 ± 2.155 3.263 
120 116.100 ± 3.378 2.909 68.667 ± 4.007 5.835 
 
 
 
Table 4.2: Release versus time profile for sutherlandin B from 
phytosomes of FDAE Sutherlandia at pH 1.2 and 6.8. 
 
 
Percentage sutherlandin 
B released at  pH 1.2 
 
Percentages sutherlandin 
B released  at pH 6.8 
 
Time (minutes) AVE ± SD %CV AVE ±SD %CV 
0 0 ± 0 0 0 ± 0 0 
5 73.600 ± 16.639 22.607 33.3 ± 4.099 12.298 
15 98.967 ± 8.271 8.358 41.7 ±0.608 1.459 
30 104.900 ± 1.868 1.781 50.4 ± 0.520 1.031 
60 161.633 ± 9.059 5.605 100.1 ± 12.002 11.990 
90 166.450 ± 3.465 2.082 106.6 ± 14.880 13.959 
120 166.950 ± 2.758 1.652 124.233 ± 6.799 5.473 
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Table 3: Drug release versus time profile for sutherlandin C from 
phytosomes of FDAE Sutherlandia at PH 1.2 and 6.8 
 
 Percentage sutherlandin 
C released  at pH 1.2 
Percentage Sutherlandin 
C released  at pH 6.8 
Time ( minutes) AVE ± SD %CV AVE ± SD %CV 
0 0 ± 0 0 0 ± 0 0 
5 84.633 ± 0.702 0.830 60.233 ± 0.603 1.001 
15 137.633 ± 17.960 13.049 72.400 ± 0.954 1.318 
30 166.400 ± 0.400 0.240 90.867 ± 1.266 1.394 
60 233.533 ± 0.208 0.089 121.067 ± 0.404 0.334 
90 237.867 ± 0.850 0.358 153.133 ± 0.850 0.555 
120 242.767 ± 0.611 0.252 156.233 ± 1.922 1.230 
 
 
Table 4:  Drug release data for sutherlandin D from phytosomes of 
FDAE Sutherlandia at PH 1.2 and 6.8 
 
 Percentage sutherlandin 
D released  at pH 1.2 
Percentage sutherlandin 
D released at  pH 6.8 
Time ( minutes) AVE ± SD %CV AVE ± SD %CV 
0 0 ± 0 0 0 ± 0 0 
5 53.900 ± 1.217 2.257 47.300 ± 2.042 4.317 
15 71.000 ± 1.900 2.676 55.567 ± 1.422 2.560 
30 82.367 ± 2.316 2.812 71.067 ± 0.839 1.180 
60 97.867 ± 24.999 25.544 97.400 ± 1.153 1.184 
90 105.300 ± 3.666 3.482 124.267 ± 4.500 3.622 
120 108.467 ± 4.932 4.547 125.800 ± 1.308 1.039 
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Table 5: Drug release data for sutherlandin A from liposomes of FDAE 
Sutherlandia at PH 1.2 and 6.8 
 Percentage Sutherlandin 
A released  at pH 1.2 
Percentage sutherlandin 
A released  at pH 6.8 
Time ( minutes) AVE ± SD %CV AVE ± SD %CV 
0 0 ± 0 0 0 ± 0 0 
5 72.9 ± 2.1 1.6 64.800 ± 1.637 2.526 
15 83.06 ± 27.1 32.7 70.933 ± 7.569 10.671 
30       92.7 ± 1.15 1.24 89.133 ± 5.346 5.998 
60 102.03 ± 0.76 0.74 109.167 ± 7.081 6.487 
90     102.150 ± 
0.071 
0.069 125.233 ± 7.022 5.607 
120 107.9 ± 4.078 3.7798 132.767 ± 6.732 5.071 
 
Table 6: Drug release versus time profile for sutherlandin B from 
liposomes of FDAE Sutherlandia at PH 1.2 and 6.8 
 
 Percentage Sutherlandin 
B released  at pH 1.2 
Percentage sutherlandin 
B released  at pH 6.8 
Time ( minutes) AVE ±SD %CV AVE ±SD %CV 
0 0 ± 0 0 0 ± 0 0 
5 130.733 ± 21.150 16.178 101.667 ± 19.19 18.883 
15 131.867 ± 30.033 22.775 120.800 ± 9.180 7.600 
30 132.050 ± 2.475 1.874 138.400 ± 4.004 2.893 
60 133.400 ± 0.424 0.318 170.867 ± 5.865 3.433 
90 135.600 ± 2.546 1.877 194.000 ± 1.414 0.729 
120 149.800 ± 4.386 2.928 195.400 ± 9.334 4.777 
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Table 7:  Drug release versus time profile data for sutherlandin C from 
liposomes of FDAE Sutherlandia at PH 1.2 and 6.8 
 Percentage sutherlandin C 
released  at pH 1.2 
Percentage sutherlandin C 
released  at pH 6.8 
Time ( 
minutes) 
AVE ± SD %CV AVE ± SD %CV 
0 0 ± 0 0 0 ± 0 0 
5 175.200 ± 1.473 0.841 149.100 ± 0.173 0.116 
15 181.633 ± 42.812 23.571 151.000 ± 0.000 0.000 
30 195.100 ± 1.493 0.765 201.933 ± 0.709 0.351 
60 216.067 ± 0.833 0.385 241.067 ± 0.115 0.048 
90 220.533 ± 0.231 0.105 241.267 ± 18.3 7.585 
120 231.967 ± 1.531 0.660 265.100 ± 0.529 0.200 
 
 
Table 8: Drug release versus time profile for sutherlandin D from 
liposomes of FDAE Sutherlandia at PH 1.2 and 6.8 
 
  Percentage Sutherlandin D 
released  at pH 1.2 
Percentage Sutherlandin 
D released at pH 6.8 
Time (minutes) AVE ± SD %CV AVE ± SD %CV 
0 0 ± 0 0 0 ± 0 0 
5 78.833 ± 2.237 2.837 115.900 ± 0.141 0.122 
15 90.933  ± 24.194 26.607 114.550 ± 2.051 1.790 
30 91.0  ± 1.947 2.139 162.500 ± 3.704 2.279 
60 83.067 ±2.150 2.589 179.000 ±0.000 0.000 
90 84.533 ± 1.361 1.610 173.667 ± 2.517 1.449 
120 105.200 ± 1.970 1.872 204.367 ± 1.704 0.834 
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